WO1995016671A1 - Triflate-mediated preparation and use of iodonium compounds - Google Patents
Triflate-mediated preparation and use of iodonium compounds Download PDFInfo
- Publication number
- WO1995016671A1 WO1995016671A1 PCT/US1994/014410 US9414410W WO9516671A1 WO 1995016671 A1 WO1995016671 A1 WO 1995016671A1 US 9414410 W US9414410 W US 9414410W WO 9516671 A1 WO9516671 A1 WO 9516671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iodonium
- aryl
- pqq
- group
- compound
- Prior art date
Links
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 title claims abstract description 92
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 title abstract description 6
- 230000001404 mediated effect Effects 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 title description 8
- -1 iodonium compound Chemical class 0.000 claims abstract description 135
- 238000000034 method Methods 0.000 claims abstract description 95
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 33
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 16
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004327 boric acid Substances 0.000 claims abstract description 15
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 15
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 claims abstract description 12
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000003239 periodontal effect Effects 0.000 claims abstract description 8
- 229940051866 mouthwash Drugs 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 28
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 25
- 229960003260 chlorhexidine Drugs 0.000 claims description 25
- 230000014759 maintenance of location Effects 0.000 claims description 19
- 210000000214 mouth Anatomy 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- JCZSQOVZJXDMTK-UHFFFAOYSA-N iodo trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OI JCZSQOVZJXDMTK-UHFFFAOYSA-N 0.000 claims description 18
- 125000001544 thienyl group Chemical group 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000003106 haloaryl group Chemical group 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- AUFSIUUJHJWECB-UHFFFAOYSA-N OS(C(F)(F)F)(=O)=O.OS(C(F)(F)F)(=O)=O.I.I Chemical class OS(C(F)(F)F)(=O)=O.OS(C(F)(F)F)(=O)=O.I.I AUFSIUUJHJWECB-UHFFFAOYSA-N 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 241000607479 Yersinia pestis Species 0.000 claims description 10
- 150000001450 anions Chemical class 0.000 claims description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 208000007565 gingivitis Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229940072107 ascorbate Drugs 0.000 claims description 8
- 235000010323 ascorbic acid Nutrition 0.000 claims description 8
- 239000011668 ascorbic acid Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 201000001245 periodontitis Diseases 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 7
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 238000006479 redox reaction Methods 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 5
- 235000010290 biphenyl Nutrition 0.000 claims description 5
- 239000004305 biphenyl Substances 0.000 claims description 5
- 241000252073 Anguilliformes Species 0.000 claims description 4
- 241000258957 Asteroidea Species 0.000 claims description 4
- 206010007134 Candida infections Diseases 0.000 claims description 4
- 241000193901 Dreissena polymorpha Species 0.000 claims description 4
- 241000235789 Hyperoartia Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 244000046146 Pueraria lobata Species 0.000 claims description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 4
- 241000287411 Turdidae Species 0.000 claims description 4
- 201000003984 candidiasis Diseases 0.000 claims description 4
- 208000002925 dental caries Diseases 0.000 claims description 4
- 239000000417 fungicide Substances 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000005997 bromomethyl group Chemical group 0.000 claims description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 3
- 230000000855 fungicidal effect Effects 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- LFMWZTSOMGDDJU-UHFFFAOYSA-N 1,4-diiodobenzene Chemical compound IC1=CC=C(I)C=C1 LFMWZTSOMGDDJU-UHFFFAOYSA-N 0.000 claims description 2
- 206010061217 Infestation Diseases 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 125000003828 azulenyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 125000001725 pyrenyl group Chemical group 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 2
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 11
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 238000006276 transfer reaction Methods 0.000 abstract description 7
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000007269 microbial metabolism Effects 0.000 abstract 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 229920001817 Agar Polymers 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 239000008272 agar Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000004293 19F NMR spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 238000002814 agar dilution Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000000440 neutrophil Anatomy 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000027756 respiratory electron transport chain Effects 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000010265 fast atom bombardment Methods 0.000 description 6
- ULAQISQDFQAUCH-UHFFFAOYSA-N trifluoromethanesulfonic acid hydroiodide Chemical class I.OS(=O)(=O)C(F)(F)F ULAQISQDFQAUCH-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000003287 bathing Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003139 biocide Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000721703 Lymantria dispar Species 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 240000000968 Parkia biglobosa Species 0.000 description 2
- 244000059266 Piper nigrescens Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 206010044032 Tooth discolouration Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- QZMUBZJJJKIXKV-UHFFFAOYSA-N pyrroloquinoline quinol Chemical compound N1=C(C(O)=O)C=C(C(O)=O)C2=C(NC(C(=O)O)=C3)C3=C(O)C(O)=C21 QZMUBZJJJKIXKV-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000036344 tooth staining Effects 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- BBOLNFYSRZVALD-UHFFFAOYSA-N 1,2-diiodobenzene Chemical compound IC1=CC=CC=C1I BBOLNFYSRZVALD-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000589873 Campylobacter concisus Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 244000251786 Cymbopogon rectus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000040311 Eucharis candida Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018296 Gingivitis ulcerative Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- XADPBTOWYAXJAY-UHFFFAOYSA-N OS(C(F)(F)F)(=O)=O.OS(C(F)(F)F)(=O)=O.IC(C=C1)=CC=C1I Chemical class OS(C(F)(F)F)(=O)=O.OS(C(F)(F)F)(=O)=O.IC(C=C1)=CC=C1I XADPBTOWYAXJAY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001384595 Paratachys micros Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- FGRVOLIFQGXPCT-UHFFFAOYSA-L dipotassium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [K+].[K+].[O-]S([O-])(=O)=S FGRVOLIFQGXPCT-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-M fluoroacetate Chemical compound [O-]C(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-M 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DXWFWRMMRJBESF-UHFFFAOYSA-N thiophene;trifluoromethanesulfonic acid Chemical compound [SH+]1C=CC=C1.[O-]S(=O)(=O)C(F)(F)F DXWFWRMMRJBESF-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- SYUVAXDZVWPKSI-UHFFFAOYSA-N tributyl(phenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CC=C1 SYUVAXDZVWPKSI-UHFFFAOYSA-N 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical class CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- FPUOKUOVIWJMDC-UHFFFAOYSA-N trimethyl-(5-trimethylsilylthiophen-2-yl)silane Chemical compound C[Si](C)(C)C1=CC=C([Si](C)(C)C)S1 FPUOKUOVIWJMDC-UHFFFAOYSA-N 0.000 description 1
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/02—Monocyclic aromatic halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/02—Monocyclic aromatic halogenated hydrocarbons
- C07C25/13—Monocyclic aromatic halogenated hydrocarbons containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/24—Halogenated aromatic hydrocarbons with unsaturated side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
Definitions
- Diphenyleneiodonium cation is an organic compound comprising polycoordinated iodine. DPI exhibits a wide range of biological activities including: 1) induction of hypoglycemia and lactic acidosis (Holland et al., J. Biol . Chem . 248:6050, (1973)); 2) inhibition of respiratory burst in neutrophils (Cross et al., Biochem . J. 237:111, (1986)); inhibition of nitric oxide synthase (Stuehr et al., FASEB J. 5:98, (1991)3); and induction of myopathy in rats (Cooper et al., J. Neurol . Sci . 83, 335, (1988); Cooper et al., Biochem . Pharmacol . 37:687,
- PQQ (methoxatin) is a bis-quinone tricarboxylic acid that is widely distributed in nature; being found in bacteria, animal and plant tissues (Mah et al., FASEB J. Abstract 7:A53, (1993); Paz et al. ASMBBIDBC-ACS Joint Meeting, Addendum, Abstract LB80, (1993); Salisbury et al., Nature 280:843, (1979); Paz et al. in Principles and Applications of Quinoproteins, Davidson, V.L. Ed.,
- PQQ is an essential nutrient in at least one mammal (Kilgore et al., Science 245:850, (1989); Smidt et al., Proc. Soc. Exp. Biol . Med . 197:19, (1991)).
- PQQ in its reduced form, PQQ(2H) is a nucleophile capable of making charge (i.e., electron) transfer complexes with a variety of electrophiles, including those associated with biological redox (i.e., oxidation-reduction) cycling (Xu et al., BBRC 193:434, (1993)).
- U.S. Patent No. 4,513,137 discloses a multi-step reflux method of making iodonium compounds comprising sulfonyloxy ligand transferring groups.
- Stang et al. J. Org. Chem. 57:1861-1864, (1992) disclose the preparation of bis-(phenyliodonium) diyne triflates.
- Zhadankin et al. (Tetradehedron Letters , 34:6853, (1993)) disclose using aryl(cyano) iodonium triflates.
- Stang and Zhdankin J. Am . Chem . Soc . 113:4571, (1991) disclose iodonium compounds, comprising acetylenyl groups.
- Chlorhexidine is a positively charged bis-biguanide with two hydrophobic terminal chlorophenyl rings linked by a hydrophobic hexamethylene chain.
- Chlorhexidine a dicationic detergent
- Chlorhexidine a dicationic detergent
- the compound exhibits anti-microbial activity against a wide variety of bacteria (reviewed in
- Chlorhexidine is used for general skin cleaning (e.g., surgical scrub), preoperative showering or bathing, and wound cleaning (Physicians' Desk Reference, pp. 1867-1868; 2374-2375 (1993)). Summary of the Invention
- iodonium triflates which do not require reflux conditions or purification (eg. crystallization and filtration) of reactants.
- the methods are useful for preparing iodonium triflates in high yield from an iodoarene, e.g, a bis-iodoarene.
- iodonium triflates which can be made by these methods include mono-, di-, and higher iodonium triflates, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties.
- the claimed methods also provide a simple way of obtaining bis-iodonium triflates comprising a heterocyclic ring, preferably a heterocyclic ring further comprising sulfur, nitrogen and/or oxygen, most preferably a thienyl, furyl or pyrrolyl ring.
- the claimed high yield methods can be used to obtain a variety of iodonium compounds comprising non-triflate anions capable of forming an ionic bound with an iodonium action.
- Novel bis-iodonium compounds made by these methods include aryl, haloaryl, halobiphenyl, alkylsilylaryl, alkylsilylalkynl,
- Iodonium compounds are capable of sequestering PQQ and thereby inhibiting PQQ-catalyzed redox reactions in vivo and in vitro .
- Iodonium compounds include mono-, di-, bis-, and higher iodononium compounds, e.g, iodonium compounds including 3-15 (inclusive) iodonium moieties.
- Mono- and bis-iodonium compounds are capable of sequestering PQQ and inhibiting critical redox cycling in cells, such as neutrophils, endothelial and muscle cells; cell
- organelles such as mitochondria and chloroplasts
- enzyme complexes capable of electron transfer reactions such as nitric oxide synthase, which comprises a nicotinamide adenine dinucleotide (NAD) moiety capable of electron transfer reactions
- NAD nicotinamide adenine dinucleotide
- flavoproteins such as cytosolic diaphorases (e.g., dihydrolipoamide dehydrogenases) which comprise a flavin adenine dinucleotide (FAD) moiety capable of electron transfer reactions
- FAD flavin adenine dinucleotide
- Iodonium compounds have useful applications.
- Iodonium compounds are also valuable topical fungicides that can be applied to the skin and are rapidly detoxified if absorbed through the skin. Iodonium compounds can be used to kill marine pests such as mussels (i.e., Zebra mussels), starfish, or lamprey eels. Iodonium compounds act as anti-inflammatory agents that reduce the severity of various infectious diseases that trigger excess inflammatory host responses.
- Iodonium compounds e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties, are effective anti-microbial agents that can alleviate periodontal disease (e.g., gingivitis, periodontitis, gingivitis-induced inflammation or thrush).
- Iodonium compounds can be applied as an oral rinse (i.e., a mouthwash), oral irrigant, periodontal pack, or topically applied in a suitable vehicle. Iodonium compounds have advantages over the use of oral antiseptics such as chlorhexidine.
- iodonium compounds can be inactivated by applying a non-toxic reducing agent (e.g., about 2-4% (w/v) sodium ascorbate or about 2-4% (w/v) sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)).
- a pharmaceutically acceptable buffer e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)
- non-toxic is meant a reducing agent which is acceptable for pharmaceutical use.
- the ability to inactivate an iodonium compound after use reduces the chance of teeth or mouth tissue damage (e.g., teeth staining or undersirable sequestration of PQQ sufficient to kill or damage mouth tissue).
- a cocktail including two or more iodonium compounds can be made where each iodonium compound exhibits a specific or very narrow anti-microbial
- the cocktail can be designed to selectively inhibit the growth of specific periodontal pathogen (s) but leave host-compatible
- the cocktail can be tailor-made for a patient suffering from particular combinations of pathogens unique to that patient. If desired, the
- cocktail can be co-administered with chlorhexidine, where the chlorhexidine is in an amount of equal anti-microbial activity.
- the anti-microbial activity of an iodonium compound can be enhanced by coadministering a boric acid solution (e.g., about 2% (w/v) boric acid in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9
- a boric acid solution e.g., about 2% (w/v) boric acid in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9
- the boric acid buffer solution can be administered prior to application of an iodonium compound in order to enhance the anti-microbial activity of the compound.
- the application of the boric acid solution is immediately prior to the application of the iodonium compound.
- boric acid solution increases the anti-microbial activity of an iodonium compound by at least 1.5 fold as determined by tests described herein, e.g., the agar dilution method described in part lX, (1), below.
- Another advantage of using an iodonium compound as anti-microbial agent is the ability to stabilize the anti-microbial activity by complexing the iodonium compound with an anion of low nucleophilicity (e.g., triflate,
- perchlorate tetrafluoroborate, hexafluorophosphate, halide, or nitrate
- an anion of higher nucleophilicity e.g., acetate or benzoate
- advantages of using a triflate anion to stablize the anti-microbial activity of an iodonium compound are at least two-fold, e.g., 1) an iodonium triflate has superior solubility, and 2) the triflate anion is
- Iodonium compounds e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties, are also useful for general skin cleaning (e.g., surgical scrub), preoperative showering or bathing, and wound cleaning.
- the anti-microbial activity of the iodonium compound can be enhanced or inactivated as described above.
- the invention features a method of making a bis- (aryl) iodonium triflate, the method
- Ar is any one of phenyl, biphenyl, or an aryl optionally substituted by one or more R 1 groups independently selected from any one of a halogen, loweralkyl, loweralkoxy,
- haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group combining said diiodoarene with an oxidizing agent capable of forming an oxidized iodoarene, preferably peracetic acid, more preferably pertrifluoracetic acid; reacting said oxidized diiodoarene with a loweralkylsilyl compound of the general formula:
- R 2 is any one of methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, iso-butyl and each R 2 is the same or different;
- R 3 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C 6 H 4 F, 4-C 6 H 4 I, loweralkylphenyl-,
- haloloweralkylphenyl- preferably 4-(CF 3 )C 6 H 4 , 3,5-(CF 3 ) 2 C 6 H 3 , halobiphenyl-, preferably 4-C 6 H 4 -C 6 H 4 -I, alkenyl, loweralkylsilylalkenyl ⁇ , alkynyl, loweralkylsilylalkynyl-,
- loweralkylsilylaryl- preferably 4-C 6 H 4 SiMe 3 , loweralkylsilylbiphenyl-,
- thienyl preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or loweralkylalkynyl-, preferably Me 3 -C ⁇ C-;
- R 4 is any one of methyl, ethyl, propyl, iso-propyl, sec-butyl, iso-butyl, preferably butyl, and each R 4 is the same or different; under conditions capable of forming a bis-(aryl) iodonium triflate of the following general formula: wherein:
- each R 1 and R 3 is the same or different
- each R 1 and R 3 is as defined above.
- a loweralkyl group is 1-12 carbon atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl group.
- a lower alkoxy group is 1-12 carbon atoms, preferably methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, or tert-butoxy group.
- haloalkyl group as used herein, contains 1-5 carbon atoms, and at least one halogen, preferably fluoromethyl, chloromethyl, bromomethyl, fluorochloromethyl,
- a halogen is a fluoro, chloro, bromo, or iodo group.
- a cycloalkyl group, as used herein, can be 3-20 carbon atoms, preferably 3 to 10 carbon atoms, most preferably 3 to 5 carbon atoms, including a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a cyclooctyl group.
- An aryl group can be 6 to 40 carbons, preferably 6 to 20 carbons, and can be any mono- or poly-cyclic (i.e., polycondensed) aromatic ring system, including phenyl, benzyl, tolyl, cumyl, alpha- and beta- naphthyl, anthracenyl, phenanthrenyl, azulenyl, pyrenyl, or napthyl substituted with one or more loweralkyl, haloalkyl or cycloalkyl groups.
- a haloaryl as used herein, can be any aryl group substituted with one or more halogen groups.
- haloaryl groups include 4-C 6 H 4 F and 4-C 6 H 4 I.
- a heteroatom substituted aryl group as used herein, can be an aryl group substituted with one or more nitro, nitroso, cyano, carboxyl, aldehydo, hydoxy, or
- An aryloxy group as used herein, can be phenoxy or benzoxy.
- a heterocyclic group as used herein, includes a pyridiyl, furyl, thienyl, pyridazinyl, or pyrrolyl group.
- a complex heterocyclic group as used herein, can be a mono- or polycyclic (i.e.,
- a loweralkylphenyl group is a phenyl group substituted with one or more loweralkyl groups.
- a haloloweralkylphenyl group is a phenyl group substituted with one or more loweralkyl groups, the loweralkyl groups further
- a preferred haloloweralkylphenyl group is a 4-(CF 3 )C 6 H 4 , or 3,5- (CF 3 ) 2 C 6 H 3 group.
- a halobiphenyl group is a biphenyl group substituted by one or more halogen groups.
- a preferred halobiphenyl group is 4-C 6 H 4 -C 6 H 4 -I.
- An alkenyl group is a linear or branched hydrocarbon of 1-5 carbon atoms with one or more carboncarbon double bonds.
- a loweralkylsilylalkenyl group can be an alkenyl group subsituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups.
- An alkynyl group is a linear or branched hydrocarbon of 1-5 carbon atoms with one or more carbon-carbon triple bonds, preferably an acetylenyl group.
- a loweralkylsilylalkynyl group, as used herein, can be any linear or branched hydrocarbon with at least one carbon-carbon triple bond substituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups.
- a preferred loweralkylsilylalkynyl group is a -C ⁇ CSiMe 3 group.
- a loweralkylsilylaryl group as used herein, is an aryl group substituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups.
- a preferred loweralkylsilylaryl group is a 4-C 6 H 4 SiMe 3 group.
- a loweralkylsilylbiphenyl, as used herein, is a biphenyl group substituted with a Si atom, the Si atom further substituted with one or more lower alkyl groups.
- a thieynl group as used herein, can be a thienyl group substituted with one or more loweralkyl, aryl, alkenyl or alkynyl groups.
- loweralkylsilylthienyl is a thienyl group substituted with a Si atom, preferably the Si atom is linked to the number two position of a thienyl ring, the Si atom further substituted with one or more loweralkyl groups.
- a preferred loweralkylsilylthienyl group is a 2-(trimethylsilyl)thienyl group.
- loweralkylalkynyl group as used herein, is an alkyne substituted with one or more loweralkyl groups.
- a preferred loweralkylalkynyl group is Me-O ⁇ C-.
- the invention features a method of making a bis-(aryl) iodonium triflate, wherein a diiodoarene is of the following general formula:
- R 4 is any one of a hydrogen, loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group.
- iodonium triflate the method including:
- R 5 is any one of methyl, ethyl, propyl, iso-propyl, or butyl, and each R 5 is the same or different;
- R 6 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C 6 H 5 F,
- loweralkylsilylaryl- preferably -C 6 H 4 SiMe 3 loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2- (trimethylsilyl) thienyl- or
- organotin compound with an iodonium trifate of the following general formula:
- R 7 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C 6 H 5 F,
- each R 6 and R 7 is the same or different; and b) each R 6 and R 7 is as defined above.
- the invention features a method of making an organo-substituted bis-iodonium triflate, the method including:
- cycloalkyl aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group
- R 8 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C 6 H 5 F, 4- C 6 H 5 I loweralkylphenyl-,
- haloloweralkylphenyl- preferably 4-C 6 H 5 I loweralkylphenyl-,
- haloloweralkylphenyl- preferably 4-(CF 3 )C 6 H 5 , 3,5-(CF 3 ) 2 C 6 H 3 halobiphenyl-, preferably 4-C 6 H 4 -C 6 H 5 I alkenyl, loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
- loweralkylsilylaryl- preferably -C 6 H 4 SiMe 3 loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
- each R 8 and R 9a is the same or different; and c) each R 8 and R 9a is as defined above.
- the invention features a bis- (aryl)iodonium salt represented by the following formula:
- Ar is any one of a phenyl, biphenyl, or an aryl group optionally substituted by one or more R 9 groups independently selected from any one of loweralkyl, loweralkoxy,
- R 9 is any one of a loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group
- R 10 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C 6 H 4 F, 4-C 6 H 4 I, loweralkylphenyl-,
- loweralkylsilylbiphenyl-thienyl preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
- each R 9 and R 10 is the same or different.
- Z- is an anion capable of forming an ionic bond with an iodonium cation sufficient to form a salt.
- preferred anions include triflate (OSO 2 CF 3 ), chloride, bromide, iodide, acid sulfate, nitrate, tetrafluoroborate, lactate (CH 3 CHOHCO 2 ),
- hexafluorophosphate alkoxide, chlorite, hypochlorite, nitrite, nitrate, azide, triiode, cyanide, hydrazide, perchlorate, haloacetate, preferably fluoroacetate, chloroacetate, bromoacetate, iodoacetate,
- fluorochloroaloweralkanoate fluorobromoloweralkanoate, chlorobromoloweralkanoate, or
- the invention features a bis-iodonium salt represented by the following formula:
- R 11a is any one of hydrogen, halogen, loweralkyl, loweralkoxy, haloalkyl-,
- R 11 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C 6 H 4 F,
- haloloweralkylphenyl- preferably 4-(CF 3 )C 6 H 4 , 3,5-(CF 3 ) 2 C 6 H 3 , halobiphenyl-, preferably 4-C 6 H 4 -C 6 H 4 -I, alkenyl, loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
- loweralkylsilylaryl- preferably 4-C 6 H 4 SiMe 3 , loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
- the invention also features a method of inhibiting a PQQ-catalyzed redox reaction, the method including
- the invention also features a method of killing unwanted vegetation, preferably
- the invention features a method of killing marine pests, preferably zebra mussels, lamprey eels and starfish, the method including:
- the invention also features a topical fungicide comprising an iodonium compound capable of being
- the invention features a method of inhibiting inflammation in a mammal, preferably a human, the method including:
- the invention features a method of inhibiting microbial growth on a tissue surface or teeth from a human or veterinary patient, the method including:
- topically applying the iodonium compound to a tissue surface or teeth in an amount sufficient to inhibit growth of susceptible microbes on the tissue surface or teeth.
- microbial growth is meant the undesired proliferation of organisms such as bacteria, yeast or fungus.
- topically applying is meant the administration of an iodonium compound to teeth or a tissue surface (either inside or outside the oral cavity) in a pharmaceutically acceptable vehicle.
- Suceptible microbes are those organisms, e.g., pathogenic oral bacteria; whose growth is completely inhibited in a test described herein, e.g., the agar dilution method described in part lX (1), below.
- the tissue surface is in the oral cavity (e.g., gums or oral mucosa), preferably in an oral cavity characterized by at least one of dental caries, plaque, gingivitis, periodontitis (e.g.
- a particular application of the invention is the inhibitation of microbial growth in
- the tissue surface is skin outside the oral cavity, e.g., a skin wound outside the oral cavity.
- the tissue surface or teeth have been subjected to dental surgery and the application of the iodonium compound is in the form of an oral rinse, oral irrigant, periodontal pack, or it is topically applied in a pharmaceutically acceptable vehicle.
- the iodonium compound after topically applying an iodonium compound to a tissue surface or teeth, is inactivated by applying a non-toxic reducing agent, preferably about 2-4% (w/v) (inclusive) ascorbate or about 2-4% (w/v) (inclusive) sodium
- a boric acid solution e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive).
- pharmaceutically acceptable buffer e.g., phosphate or bicarbonate buffer at pH 5-9 (inclusive)
- the boric acid solution is administered immediately prior to the application of the iodonium compound.
- the enhancement of the anti-microbial activity of an iodonium compound is determined by tests described below, e.g., the agar dilution method described in part lX (1), below.
- the method further includes providing and applying chlorhexidine and an iodonium compound in an amount sufficient to inhibit the growth of susceptible microbes on a tissue surface or teeth.
- the chlorhexidine and iodonium compound are each applied in amounts of equal anti-microbial activity as determined by methods described herein, e.g., the agar dilution method described in part lX (1), below.
- the method further includes providing and applying two or more iodonium compounds, either by themselves, or in combination with chlorhexidine, where each compound is in an amount of equal anti-microbial activity as defined by methods described herein, e.g., the agar dilution method
- Fig. 1 depicts chemical formulae of PQQ(l), DPI (2), and selected mono-(3,4) and bis(5-8)-iodonium compounds synthesized by triflate-mediated synthetic methods of the invention.
- Fig. 2a and Fig. 2b show general schemes for preparing iodonium compounds:
- Fig. 2b Scheme 2: bis-(aryliodonium) thiophene triflate prepared from reaction of an aryl (cyano) iodonium triflate and 2,5-bis(tributyltin)thiophene.
- Table 1 shows the inhibition of PQQ-catalyzed redox cycling by selected mono- and bis- iodonium
- Tables 2 and 3 show the activity of iodonium compounds against oral bacteria.
- Tables 4 and 5 show the activity of iodonium compounds against streptococci isolated from patients with refractory peritonitis.
- Iodonium compounds can be analyzed by HRMS (High Resolution Mass spectroscopy). The expected spectral values of the proposed iodonium compounds can be found below. The spectral values of related iodonium compounds have been published (Watanabe et al., Curr. Ther. Res . 44:896, (1988); Hobara et al., Pharmacology 37:264, (1988);
- Iodonium compounds that sequester PQQ inhibit the PQQ redox-cycling assay by preventing the reduction of PQQ to PQQH 2 .
- alkynl mono-iodonium compounds (3a-d) is comparable to inhibition of PQQ by Ph 2 I + (BPI) and DPI.
- the bis-iodonium compounds (5a-h, 6a-b, 7, 8a-b, in Fig. 1) are the most effective in inhibiting redox-cycling.
- the data indicate that bis-iodonium salts 5a-c, 8a-b are the most effective at sequestering PQQ and
- Compounds 5a-c, 8a-b are 100-1000X better than mono-iodonium compounds at sequestering PQQ and inhibiting electron transfer in the redox-cyciing assay.
- iodonium compounds are capable of selective cell permeability and are capable of
- iodonium compounds preferably bis-iodonium compounds, are useful as effective and selective
- inhibitors of electron transfer reactions involving PQQ Such iodonium compounds inhibit in vitro and in vivo enzymatic reactions involving electron transfer in a wide variety of bacteria, fungi, plants, and animals, thereby serving as effective biocidal agents.
- the in vitro redox-cycling assay described above can be used to screen iodonium compounds of the invention for the ability to sequester PQQ and inhibit redox-cycling. Iodonium compounds that sequester PQQ and inhibit redox-cycling in vitro will serve as effective biocidal agents.
- Aryl (cyano) iodonium triflates (14, Fig. 2) were prepared from bis(trifluoroacetoxy)iodoarenes,
- Iodonium compounds 3, 4, 6 and 7 in Fig. 1 were prepared by published methods (Bachi et al., J. Org. Chem . 56:3912, (1991); Stang et al., J. Heterocyclic . Chem . 29:815, (1992); Stang et al., J. Org. Chem . , 57:1861, (1992); Stang et al., J. Am . Chem . Soc . 114:4411, (1992)). All solvents used were dried by distillation over CaH 2 . The reaction flasks were flame-dried and flushed with
- 5b Yield 0.7 g (90%); mp 280-290° C (decomp.). 5c: Yield 0.95 g (92%); mp 270-275° C (decomp.).
- methylethynyltributytin and phenyltributyltin can be substituted for 13 (Fig. 2b) in order to obtain the corresponding bis(aryliodonium) theophene.
- Iodonium compounds of the invention are useful as herbicides which kill unwanted vegetation, e.g., the kudzu vine; as insecticides which kill insects, e.g., the gypsy moth; and as agents which kill marine pests, e.g., zebra mussels, starfish, and lamprey eels.
- an iodonium triflate or other iodonium salt of the invention can be dispersed on an inert finely divided solid (e.g., silica) and employed as a dust. Such a mixture can be used directly on plants or insects.
- an iodonium triflate or other iodonium salt of the invention can be employed as a spray or emulsion by dissolving in water, preferably a solution of 90% by weight water and 10% by weight dimethylsulfoxide (DMSO) or 10% by weight acetonitrile or 10% by weight dimethylformanide.
- DMSO dimethylsulfoxide
- Preferred compositions contain from 0.0001% to 50% by weight of an iodonium triflate or other iodonium salt of the invention.
- An iodonium triflate or other iodonium salt of the invention can be delivered in a pharmaceutically acceptable carrier to a skin surface subject to fungal infection.
- suitable carriers include water, oils such as mineral oils, soybean oil and the like, creams or gels comprising glycerol and/or potassium, ammonium or sodium stearate, and water.
- an iodonium triflate or other iodonium salt of the invention can be used in a carrier at 0.05% by weight. Examples of other pharmaceutically acceptable carriers for topical administration can be found in Remington 's Pharmaceutical Sciences, Mack
- Macrophages and neutrophils mediate inflammatory reactions associated with trauma, pulmonary emphysema, cystic fibrosis, bronchitis, psoriasis, arthritis, and rheumatoid arthritis, among other inflammatory diseases. Tissue destruction by macrophages and neutrophils has been extensively reviewed (Weiss, S.J. N . Engl . J. Med . 320, 365 (1989); Lehrer, R.I. et al. Ann. Intern . Med . 109, 127, (1988); Malech, H.L. et al. Ann. Intern . Med . 317, 687, (1987)). Both cell types expose phagocytosed cells and/or tissue to free radical species such as superoxide (O 2 -), hydroxyl radical and hypochlorite.
- Macrophages and neutrophils produce free radical species by using known redox-cycling reactions. Without wishing to bind our to any particular theory, it is
- an iodonium compound is at a
- In vivo model systems for testing the activity of agents that inhibit neutrophils or macrophage free radical generation are also known in the art, for example rodent models are known and can be used to test iodonium compounds of the invention for anti-inflammatory activity in vivo.
- iodonium compounds e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., compounds which include 3-15 (inclusive) iodonium moieties; whenever
- chlorhexidine administration is indicated, but with superior results.
- iodonium compounds are anti-microbial agents which can alleviate juvenile and adult periodontal diseases such as gingivitis, periodontitis (e.g., refractory peritontitis),
- iodonium compounds are also effective anti-microbial agents for use in general or preoperative skin cleaning,
- iodonium compounds can be inactivated after use by briefly applying a non-toxic reducing agent.
- a non-toxic reducing agent suitable for use include 2-4% (w/v) sodium ascorbate or 2-4% sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer at pH 5-9 (inclusive)).
- a pharmaceutically acceptable buffer e.g., phosphate or bicarbonate buffer at pH 5-9 (inclusive)
- Other pharmaceutically acceptable salts of ascorbate and thiosulfate can also be used, e.g., potassium ascorbate and potassium thiosulfate.
- non-toxic reducing agents can be identified by combining a molar excess (e.g., a 1.5 fold molar excess) of the reducing agent with a particular iodonium compound and evaluating the anti-microbial activity of the treated iodonium compound in the agar dilution method described in part IX (1), below.
- a molar excess e.g., a 1.5 fold molar excess
- an acceptable non-toxic reducing agent will eliminate the anti-microbial activity of the iodonium compound.
- the anti-microbial activity of an iodonium compound can be enhanced by administering, either prior to or during the topical application of the iodonium compound, a 2-4% (w/v) (inclusive) boric acid solution in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate at pH 5-9 (inclusive)).
- a pharmaceutically acceptable buffer e.g., phosphate or bicarbonate at pH 5-9 (inclusive)
- the boric acid solution is administered immediately prior to the application of the iodonium compound.
- the enhancement of the anti-microbial activity of an iodonium compound is at least 1.5 fold and can be determined by tests described herein, e.g., the agar dilution method described in part lX (1), below.
- An iodonium compound e.g., a mono-, di-, bis-, or higher iodonium compound, e.g., a compound including 3-15 (inclusive) iodonium moieties, can be used with one or more other iodonium compounds or optionally, combined with chlorhexidine, each compound in amounts of equal anti-microbial activity (determined by methods described below, e.g., the agar dilution method described in part IX (1), below).
- the combination of one or more iodonium compounds or optionally, chlorhexidine will reduce the danger of selecting resistant oral flora.
- An iodonium compound, either alone, with one or more other iodonium compounds, or optionally combined with chlorhexidine can also be used in: 1) general or preoperative skin cleaning
- Agar Dilution Method Iodonium compounds were tested for anti-microbial activity against reference strains of oral bacteria. These reference strains included 48 subgingival species (Tables 2 and 3) and 26 strains of streptococci isolated from patients with refractory periodontitis (Tables 3 and 4).
- oral antiseptic treatment including
- the MIC was defined as the minimum concentration of an iodonium compound necessary to completely inhibit the growth of a reference strain of bacteria.
- composition of the agar medium is disclosed below:
- Agar medium was sterilized in individual test tubes (1 test tube per Petri plate) by autoclaving at 121°C for 15 min. The sterilized agar medium was subsequently cooled in a 50°C water bath. The volume in each tube was adjusted with water so that the final volume approximate 40 ml when the filter-sterilized bis-iodonium compounds were added to the agar medium.
- Bis-iodonium compounds 6a, 8a, and 8b were each dissolved in 5 ml of dimethyl sulfoxide, then distilled water was added to adjust the final
- concentration of bis-iodonium compound in 40 mls of agar medium) to 2 ⁇ g/ml, 4 ⁇ g/ml, 8 ⁇ g/ml, 16 ⁇ g/ml, 32 ⁇ g/ml or 64 ⁇ g/ml.
- a solution was prepared without any added bis-iodonium compound. Each solution was subsequently filter sterilized by passage through a 0.22 ⁇ m Nalgene filter. After addition of control or bis-iodonium compound containing solutions into about 40 mls agar medium, the agar medium was aseptically dispensed into plastic microtiter dishes. The agar medium was allowed to set overnight.
- each bacterial strain suspension 100 ⁇ l of each bacterial strain suspension was placed in the microtiter plate containing either control agar medium or agar medium with 2 ⁇ g/ml, 4 ⁇ g/ml, 8 ⁇ g/ml, 16 ⁇ g/ml, 32 ⁇ g/ml or 64 ⁇ g/ml of a bis-iodonium compound. Because of the large number of individual bacterial species tested, an MIC 2000 inoculator was used to transfer 1.5 ⁇ l of each inoculum to the surface of a microtiter plates. Control plates were inoculated at the beginning and end of the series of inoculations to verify aseptic experimental conditions. These plates were used to indicate that the inoculum was present and viable throughout the series. This was confirmed for all species.
- Tables 2, 3, 4 and 5 show that iodonium compounds inhibit the growth of a wide variety of bacteria; several iodonium compounds exhibit anti-microbial activity which is superior to that of chlorhexidine.
- table 2 shows that iodonium compounds inhibit the growth of several subgingival bacterial species below 64 ⁇ g/ml.
- Oral bacteria such as B . forsythus, C . rectus, F .
- nucleatum subspecies P . gingivalis, P . intermedia, P. nigrescens and P. micros, were each sensitive to compound 8b ( a bis-iodonium compound) at low levels ( ⁇ 16 ⁇ g/ml).
- P. intermedia and P. nigrescens were especially sensitive to iodonium compounds 6a and 8b.
- Table 4 shows that iodonium compounds inhibit the growth of streptococci isolated from patients with refractory periodontitis. For example, strain HA45 was inhibited by iodonium compounds 6a, 8a, and 8b.
- Tables 3 and 5 point out that several iodonium compounds exhibit a lower MIC (i.e. better anti-microbial activity) than chlorhexidine.
- compounds 4a, 5b and 4 (a mono-iodonium compound) inhibit the growth of C. concisus at levels 2-4 fold lower than chlorhexidine.
- the data indicate that mono-, di-, bi-, and higher iodonium compounds, e.g., compounds including 3-15 (inclusive) iodonium moieties, can be used to inhibit the growth of a variety of oral bacteria on a tissue surface or teeth from a human or veterinary patient.
- Iodonium compounds can be tested for anti-microbial activity by other well-known methods. Such tests are useful for evaluating the anti-microbial activity of an iodonium compound.
- a paper disc can be impregnated with an iodonium compound and placed on the surface of an agar plate which includes a lawn of any gram-negative or gram-positive bacteria, for example, any bacteria of the genus streptococci (gram negative) or staphylococci (gram positive).
- a paper disc can be impregnated with an iodonium compound and placed on the surface of an agar plate which includes a lawn of any gram-negative or gram-positive bacteria, for example, any bacteria of the genus streptococci (gram negative) or staphylococci (gram positive).
- bacteria can include pathogenic bacteria found inside the oral cavity or outside the oral cavity, e.g., on a skin surface.
- concentration of a particular Iodonium compound in the paper disc can be varied by serial dilution in order to determine the MIC. Standard
- anti-fungal activity of an iodonium compound against opportunistic infections of the oral cavity for example, thrush fungus (i.e. Candida albicans) can be examined by the method of Budtz-Jorgensen E. and Loe, H. (Scand. Dent. J. Dent. Res. 80, 457 (1972).
- anti-plaque activity of an iodonium compound can be evaluated by topically applying (e.g. rinsing) about 10 ml of a 0.2% (w/v) solution of the iodonium compound, followed by an examination of plague deposits or salivary bacteria (Loe, H. and Schiott C.R., J. Periodont. Res 5, 79 (1970); Schiott, C.R. et al. J. Periodont Res. 5, 84 (1970)).
- chlorhexidine can be coadministered (at a concentration giving equivalent anti-microbial activity) with an iodonium compound in order to detect synergistic anti-microbial effects between
- An iodonium compound which inhibits the growth of susceptible microbes by any above-described test can be used as an oral rinsing agent, oral irrigating agent, subgingival irrigating agent, or periodontal pack.
- an iodonium salt e.g., the gluconate salt of compounds 6a, 8a or 8b
- water, about 10% alcohol, a sorbitan stearate, and a flavoring agent e.g., the gluconate salt of compounds 6a, 8a or 8b
- the effective final concentration of an iodonium compound is at least 1 ⁇ g/ml (between 0.001% and 2% w/v (inclusive)).
- administration of an iodonium compound is followed by applying a non-toxic reducing agent, e.g. about 2-4% (w/v) sodium ascorbate or about 2-4% (w/v) sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)) in order to inactivate (i.e. chemically reduce) the compound.
- a pharmaceutically acceptable buffer e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)
- the non-toxic reducing agent is desirably in molar excess with respect to the applied iodonium compound (at least 1.5-fold molar excess).
- the activity of an iodonium is desirably in molar excess with respect to the applied iodonium compound (
- iodonium compound can be enhanced by topically applying (either before or during application of the iodonium compound) about 2% boric acid in pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)).
- pharmaceutically acceptable buffer e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)
- a non-toxic reducing agent or boric acid solution is applied for at least 1 minute, followed by rinsing with a
- an oral rinse which includes an iodonium
- compound can be inactivated by rinsing 3 times (about 30 seconds each) with a 2% (w/v) ascorbate solution, followed by one (about 10 second) water rinse.
- an agent which inhibits the growth of susceptible microbes outside the oral cavity e.g., use as a skin cleanser (e.g., surgical scrub), preoperative showering or bathing, or wound cleaner; an iodonium salt (e.g., the gluconate salt of compounds 6a, 8a or 8b) can be dissolved in 4% isopropyl alcohol at a final
- a pharmaceutically acceptable carrier which includes a detergent and/or emollient.
- a pharmaceutically acceptable carrier which includes a detergent and/or emollient.
- antiseptic may be optionally added in an amount of equal anti-microbial activity (determined by methods described herein, e.g., the agar dilution method described in part lX, (1), above).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Methods of producing iodonium compounds by triflate-mediated iodonium transfer reactions are disclosed. Iodonium compounds sequester PQQ and inhibit PQQ-catalyzed cellular redox-cycling reactions involved in microbial metabolism and in host responses, e.g. inflammation. Iodonium compounds can be used as anti-microbial agents for human or veterinary use, particularly as an oral rinse, oral irrigant, or periodontal pack. The anti-microbial activity of an iodonium compound can be controlled by administering a non-toxic reducing agent or boric acid solution.
Description
TRIFLATE-MEDIATED PREPARATION AND USE OF IODONIUM
COMPOUNDS Statement as to Federally Sponsored Research
This work was supported by NIA 07723, DE 08649, National Dairy Promotion & Research Board Grant
administered by the National Dairy Council at Harvard and by the NCI of NIH [2ROCA16903] at Utah. The U.S.
government has certain rights to this invention.
Background of the Invention
Diphenyleneiodonium cation (DPI) is an organic compound comprising polycoordinated iodine. DPI exhibits a wide range of biological activities including: 1) induction of hypoglycemia and lactic acidosis (Holland et al., J. Biol . Chem . 248:6050, (1973)); 2) inhibition of respiratory burst in neutrophils (Cross et al., Biochem . J. 237:111, (1986)); inhibition of nitric oxide synthase (Stuehr et al., FASEB J. 5:98, (1991)3); and induction of myopathy in rats (Cooper et al., J. Neurol . Sci . 83, 335, (1988); Cooper et al., Biochem . Pharmacol . 37:687,
(1988)).
PQQ (methoxatin), is a bis-quinone tricarboxylic acid that is widely distributed in nature; being found in bacteria, animal and plant tissues (Mah et al., FASEB J. Abstract 7:A53, (1993); Paz et al. ASMBBIDBC-ACS Joint Meeting, Addendum, Abstract LB80, (1993); Salisbury et al., Nature 280:843, (1979); Paz et al. in Principles and Applications of Quinoproteins, Davidson, V.L. Ed.,
Marcell Dekker, Inc.: New York, pp. 381-393 (1992)). PQQ is an essential nutrient in at least one mammal (Kilgore et al., Science 245:850, (1989); Smidt et al., Proc. Soc. Exp. Biol . Med . 197:19, (1991)). PQQ in its reduced form, PQQ(2H), is a nucleophile capable of making charge (i.e., electron) transfer complexes with a variety of
electrophiles, including those associated with biological redox (i.e., oxidation-reduction) cycling (Xu et al., BBRC 193:434, (1993)).
Administration of a therapeutic composition comprising PQQ affords protection against: 1)
hepatotoxicity (Watanabe et al., Curr . Ther. Res . 44:896, (1988)); 2) cataract formation (Nishigori et al., Life Sci . 45: 593, (1989)); 4) inflammation (Hamagishi et al., J. Pharmacol . Exp. Ther. 255:980, (1990)); 5)
neurotoxicity (Aizenman et al., J. Neurosci . 12:2362,
(1992)); and 6) stroke-induced brain necrosis (Gardner et al., Society for Neuroscience 18:A321.6, (1992).
U.S. Patent No. 4,513,137 discloses a multi-step reflux method of making iodonium compounds comprising sulfonyloxy ligand transferring groups. Stang et al. (J. Org. Chem. 57:1861-1864, (1992)) disclose the preparation of bis-(phenyliodonium) diyne triflates. Zhadankin et al. (Tetradehedron Letters , 34:6853, (1993)) disclose using aryl(cyano) iodonium triflates. Stang and Zhdankin (J. Am . Chem . Soc . 113:4571, (1991)) disclose iodonium compounds, comprising acetylenyl groups. U.S. patents
3,622,586; 3,944,498; 3,422,152; 3,896,140; 3,734,928;
3,759,989; 3,712,920 each describe iodonium compounds.
Chlorhexidine is a positively charged bis-biguanide with two hydrophobic terminal chlorophenyl rings linked by a hydrophobic hexamethylene chain.
Chlorhexidine, a dicationic detergent, is used as an oral rinse, irrigant, or periodontal pack against periodontal disease; the compound exhibits anti-microbial activity against a wide variety of bacteria (reviewed in
Greenstein et al. J. Periodontal. 57, 370-377 (1986)). Chlorhexidine is used for general skin cleaning (e.g., surgical scrub), preoperative showering or bathing, and wound cleaning (Physicians' Desk Reference, pp. 1867-1868; 2374-2375 (1993)).
Summary of the Invention
We have found simple methods of making iodonium triflates which do not require reflux conditions or purification (eg. crystallization and filtration) of reactants. The methods are useful for preparing iodonium triflates in high yield from an iodoarene, e.g, a bis-iodoarene. Examples of other iodonium triflates which can be made by these methods include mono-, di-, and higher iodonium triflates, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties. The claimed methods also provide a simple way of obtaining bis-iodonium triflates comprising a heterocyclic ring, preferably a heterocyclic ring further comprising sulfur, nitrogen and/or oxygen, most preferably a thienyl, furyl or pyrrolyl ring. By using simple anion substitution steps known in the art, the claimed high yield methods can be used to obtain a variety of iodonium compounds comprising non-triflate anions capable of forming an ionic bound with an iodonium action. Novel bis-iodonium compounds made by these methods include aryl, haloaryl, halobiphenyl, alkylsilylaryl, alkylsilylalkynl,
alkylsilylbiphenyl, and alkylsilylthienyl derivatives, as well as aryl and haloaryl bis-iodonium thiophene
compounds.
We have also found that iodonium compounds are capable of sequestering PQQ and thereby inhibiting PQQ-catalyzed redox reactions in vivo and in vitro . Iodonium compounds, as used herein, include mono-, di-, bis-, and higher iodononium compounds, e.g, iodonium compounds including 3-15 (inclusive) iodonium moieties. Mono- and bis-iodonium compounds are capable of sequestering PQQ and inhibiting critical redox cycling in cells, such as neutrophils, endothelial and muscle cells; cell
organelles, such as mitochondria and chloroplasts; enzyme complexes capable of electron transfer reactions such as
nitric oxide synthase, which comprises a nicotinamide adenine dinucleotide (NAD) moiety capable of electron transfer reactions; flavoproteins such as cytosolic diaphorases (e.g., dihydrolipoamide dehydrogenases) which comprise a flavin adenine dinucleotide (FAD) moiety capable of electron transfer reactions, and other enzyme complexes comprising moieties capable of electron
transfer reactions, including enzyme complexes capable of redox-cycling reactions. We have also found that certain iodonium compounds can exhibit PQQ sequestring and detergent activities which attact anti-microbial
activity.
Iodonium compounds have useful applications.
These applications include use as pesticides, e.g., insecticides and herbicides; for example, killing unwanted vegetation, such as the kudzu vine, or damaging insects such as the gypsy moth. Iodonium compounds are also valuable topical fungicides that can be applied to the skin and are rapidly detoxified if absorbed through the skin. Iodonium compounds can be used to kill marine pests such as mussels (i.e., Zebra mussels), starfish, or lamprey eels. Iodonium compounds act as anti-inflammatory agents that reduce the severity of various infectious diseases that trigger excess inflammatory host responses.
Iodonium compounds, e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties, are effective anti-microbial agents that can alleviate periodontal disease (e.g., gingivitis, periodontitis, gingivitis-induced inflammation or thrush). Iodonium compounds can be applied as an oral rinse (i.e., a mouthwash), oral irrigant, periodontal pack, or topically applied in a suitable vehicle. Iodonium compounds have advantages over the use of oral antiseptics such as
chlorhexidine. For example, iodonium compounds can be inactivated by applying a non-toxic reducing agent (e.g., about 2-4% (w/v) sodium ascorbate or about 2-4% (w/v) sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)). By "non-toxic" is meant a reducing agent which is acceptable for pharmaceutical use. The ability to inactivate an iodonium compound after use reduces the chance of teeth or mouth tissue damage (e.g., teeth staining or undersirable sequestration of PQQ sufficient to kill or damage mouth tissue).
In another example of the advantages of using an iodonium compound as an anti-microbial agent inside the oral cavity, a cocktail including two or more iodonium compounds can be made where each iodonium compound exhibits a specific or very narrow anti-microbial
activity against certain microbes, e.g., the cocktail can be designed to selectively inhibit the growth of specific periodontal pathogen (s) but leave host-compatible
bacteria unharmed. Unlike using chlorhexidine as an anti-microbial agent, the cocktail can be tailor-made for a patient suffering from particular combinations of pathogens unique to that patient. If desired, the
cocktail can be co-administered with chlorhexidine, where the chlorhexidine is in an amount of equal anti-microbial activity.
In another example of the advantages of using an iodonium compound as anti-microbial agent (either inside or outside the oral cavity), the anti-microbial activity of an iodonium compound can be enhanced by coadministering a boric acid solution (e.g., about 2% (w/v) boric acid in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9
(inclusive)). Alternatively, the boric acid buffer solution can be administered prior to application of an
iodonium compound in order to enhance the anti-microbial activity of the compound. Preferably, the application of the boric acid solution is immediately prior to the application of the iodonium compound. Without wishing to be bound to any specific theory, it appears that boric acid is capable of forming a chelate complex with
endogenous ascorbate (i.e., ascorbate naturally present in tissue), thereby preventing endogenous ascorbate from inactivating an applied iodonium compound. By "enhanced" is meant that the boric acid solution increases the anti-microbial activity of an iodonium compound by at least 1.5 fold as determined by tests described herein, e.g., the agar dilution method described in part lX, (1), below.
Another advantage of using an iodonium compound as anti-microbial agent (either inside or outside the oral cavity) is the ability to stabilize the anti-microbial activity by complexing the iodonium compound with an anion of low nucleophilicity (e.g., triflate,
perchlorate, tetrafluoroborate, hexafluorophosphate, halide, or nitrate), rather than an anion of higher nucleophilicity (e.g., acetate or benzoate). The
advantages of using a triflate anion to stablize the anti-microbial activity of an iodonium compound are at least two-fold, e.g., 1) an iodonium triflate has superior solubility, and 2) the triflate anion is
biologically innocuous.
Iodonium compounds, e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., iodonium compounds including 3-15 (inclusive) iodonium moieties, are also useful for general skin cleaning (e.g., surgical scrub), preoperative showering or bathing, and wound cleaning. The anti-microbial activity of the iodonium compound can be enhanced or inactivated as described above.
In general, the invention features a method of making a bis- (aryl) iodonium triflate, the method
wherein:
a) Ar is any one of phenyl, biphenyl, or an aryl optionally substituted by one or more R1 groups independently selected from any one of a halogen, loweralkyl, loweralkoxy,
haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; combining said diiodoarene with an oxidizing agent capable of forming an oxidized iodoarene, preferably peracetic acid, more preferably pertrifluoracetic acid; reacting said oxidized diiodoarene with a loweralkylsilyl compound of the general formula:
(R2)3Si-R3
wherein:
a) R2 is any one of methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl, iso-butyl and each R2 is the same or different; b) R3 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C6H4F, 4-C6H4I, loweralkylphenyl-,
haloloweralkylphenyl-, preferably
4-(CF3)C6H4, 3,5-(CF3)2C6H3, halobiphenyl-, preferably 4-C6H4-C6H4-I, alkenyl, loweralkylsilylalkenyl¬, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-, preferably 4-C6H4SiMe3, loweralkylsilylbiphenyl-,
thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or loweralkylalkynyl-, preferably Me3-C≡C-;
and
a loweralkyIsilyltriflate, preferably
trimethylsilyltriflate (Me3SiOSO2CF3), of the general formula
(R4)3-SiOSO2CF3 wherein:
a) R4 is any one of methyl, ethyl, propyl, iso-propyl, sec-butyl, iso-butyl, preferably butyl, and each R4 is the same or different; under conditions capable of forming a bis-(aryl) iodonium triflate of the following general formula:
wherein:
a) each R1 and R3 is the same or different; and
b) each R1 and R3 is as defined above.
A loweralkyl group, as used herein, is 1-12 carbon atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl group. A lower
alkoxy group, as used herein, is 1-12 carbon atoms, preferably methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, or tert-butoxy group. A
haloalkyl group, as used herein, contains 1-5 carbon atoms, and at least one halogen, preferably fluoromethyl, chloromethyl, bromomethyl, fluorochloromethyl,
fluorobromomethyl, chlorobromomethyl,
fluorochlorobromomethyl trifluoromethyl, trichloromethyl, or tribromomethyl group. A halogen is a fluoro, chloro, bromo, or iodo group. A cycloalkyl group, as used herein, can be 3-20 carbon atoms, preferably 3 to 10 carbon atoms, most preferably 3 to 5 carbon atoms, including a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a cyclooctyl group. An aryl group, as used herein, can be 6 to 40 carbons, preferably 6 to 20 carbons, and can be any mono- or poly-cyclic (i.e., polycondensed) aromatic ring system, including phenyl, benzyl, tolyl, cumyl, alpha- and beta- naphthyl, anthracenyl, phenanthrenyl, azulenyl, pyrenyl, or napthyl substituted with one or more loweralkyl, haloalkyl or cycloalkyl groups. A haloaryl as used herein, can be any aryl group substituted with one or more halogen groups. Preferred haloaryl groups include 4-C6H4F and 4-C6H4I. A heteroatom substituted aryl group, as used herein, can be an aryl group substituted with one or more nitro, nitroso, cyano, carboxyl, aldehydo, hydoxy, or
loweralkoxy groups. An aryloxy group, as used herein, can be phenoxy or benzoxy. A heterocyclic group, as used herein, includes a pyridiyl, furyl, thienyl, pyridazinyl, or pyrrolyl group. A complex heterocyclic group, as used herein, can be a mono- or polycyclic (i.e.,
polycondensed) hydrocarbon ring or ring system comprising N, O, or S, for example, a pyrazinyl, acridinyl, or phenanthridinyl group. A loweralkylphenyl group, as used herein, is a phenyl group substituted with one or more
loweralkyl groups. A haloloweralkylphenyl group, as used herein, is a phenyl group substituted with one or more loweralkyl groups, the loweralkyl groups further
substituted by one or more halogen groups. A preferred haloloweralkylphenyl group is a 4-(CF3)C6H4, or 3,5- (CF3)2C6H3 group. A halobiphenyl group, as used herein, is a biphenyl group substituted by one or more halogen groups. A preferred halobiphenyl group is 4-C6H4-C6H4-I. An alkenyl group, as used herein, is a linear or branched hydrocarbon of 1-5 carbon atoms with one or more carboncarbon double bonds. A loweralkylsilylalkenyl group, as used herein, can be an alkenyl group subsituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups. An alkynyl group, as used herein, is a linear or branched hydrocarbon of 1-5 carbon atoms with one or more carbon-carbon triple bonds, preferably an acetylenyl group. A loweralkylsilylalkynyl group, as used herein, can be any linear or branched hydrocarbon with at least one carbon-carbon triple bond substituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups. A preferred loweralkylsilylalkynyl group is a -C≡CSiMe3 group. A loweralkylsilylaryl group, as used herein, is an aryl group substituted with a Si atom, the Si atom further substituted with one or more loweralkyl groups. A preferred loweralkylsilylaryl group is a 4-C6H4SiMe3 group. A loweralkylsilylbiphenyl, as used herein, is a biphenyl group substituted with a Si atom, the Si atom further substituted with one or more lower alkyl groups. A thieynl group, as used herein, can be a thienyl group substituted with one or more loweralkyl, aryl, alkenyl or alkynyl groups. A
loweralkylsilylthienyl, as used herein, is a thienyl group substituted with a Si atom, preferably the Si atom is linked to the number two position of a thienyl ring, the Si atom further substituted with one or more
loweralkyl groups. A preferred loweralkylsilylthienyl group is a 2-(trimethylsilyl)thienyl group. A
loweralkylalkynyl group, as used herein, is an alkyne substituted with one or more loweralkyl groups. A preferred loweralkylalkynyl group is Me-O≡C-.
In a related aspect, the invention features a method of making a bis-(aryl) iodonium triflate, wherein a diiodoarene is of the following general formula:
wherein:
a) n=1; and R4 is attached to any one of an ortho, or meta ring position; or b) n=2, 3, or 4 and each R4 is individually attached to two or more ortho or meta ring positions and each R4 is the same of different;
and
c) R4 is any one of a hydrogen, loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl,
heteroatom substituted aryl, aryloxy, or heterocyclic group.
A method of making an organo-substituted
iodonium triflate, the method including:
obtaining an organotin compound of the general formula:
R6-Sn(R5)3 wherein:
a) R5 is any one of methyl, ethyl, propyl, iso-propyl, or butyl, and each R5 is the same or different; b) R6 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C6H5F,
4-C6H5I loweralkylphenyl-,
haloloweralkylphenyl-, preferably
4-(CF3)C6H5, 3,5-(CF3)2C6H3 halobiphenyl-, preferably 4-C6H4-C6H5I, alkenyl, loweralkylsilylalkenyl-, alkynyl,
loweralkylsilylalkynyl-,
loweralkylsilylaryl-, preferably -C6H4SiMe3 loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2- (trimethylsilyl) thienyl- or
loweralkylalkynyl-, preferably Me-C≡C-; combining the organotin compound with an iodonium trifate of the following general formula:
R7-I+-CN[OSO2CF3]-
wherein:
a) R7 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C6H5F,
4-C6H5I loweralkylphenyl-,
haloloweralkylphenyl-, preferably
4-(CF3)C6H5, 3,5-(CF3)2C6H3 halobiphenyl-, preferably 4-C6H4-C6H5I alkenyl, loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-,
preferably -C5H4SiMe3
loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
loweralkylalkynyl-, preferably Me-C≡C-; under conditions capable of forming an organo-substituted iodonium triflate of the following general formula:
R6-I+-R7 [OSO2CF3]- wherein:
a) each R6 and R7 is the same or different; and b) each R6 and R7 is as defined above.
In a related aspect, the invention features a method of making an organo-substituted bis-iodonium triflate, the method including:
obtaining an organostannane of the general formula:
a) X is either S or O; or X is NH; b) R8a is any one of methyl, ethyl, propyl, iso-propyl, or butyl, and each R8a is the same or different; c) n=1; and R9a is attached to any one of the number 3 or 4 ring positions; or n=2 and each R9a is individually attached to both the number 3 and 4 ring positions and each R9a is the same or different; d) R9a is any one of hydrogen, halogen, loweralkyl, loweralkoxy, haloalkyl-,
cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group;
and
combining said organostannane with an iodonium triflate of the general formula:
R8-I+-CN[OSO2CF3]-
wherein:
a) R8 is any one of an aryl, preferably phenyl, haloaryl-, preferably 4-C6H5F, 4- C6H5I loweralkylphenyl-,
haloloweralkylphenyl-, preferably
4-C6H5I loweralkylphenyl-,
haloloweralkylphenyl-, preferably 4-(CF3)C6H5, 3,5-(CF3)2C6H3 halobiphenyl-, preferably 4-C6H4-C6H5I alkenyl, loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-, preferably -C6H4SiMe3 loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
loweralkylalkynyl-, preferably Me-C≡C-; under conditions capable of forming an organo-substituted bis-iodonium triflate of the following general formula:
wherein:
a) X is either S or O; or X is NH; b) each R8 and R9a is the same or different; and c) each R8 and R9a is as defined above. In another aspect, the invention features a bis- (aryl)iodonium salt represented by the following formula:
wherein:
a) Ar is any one of a phenyl, biphenyl, or an aryl group optionally substituted by one or more R9 groups independently selected from any one of loweralkyl, loweralkoxy,
haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; b) R9 is any one of a loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; c) R10 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C6H4F, 4-C6H4I, loweralkylphenyl-,
haloloweralkylphenyl-, preferably
4-(CF3)C6H4, 3,5-(CF3)2C6H3, halobiphenyl-, preferably 4-C6H4-C6H4-I, alkenyl,
loweralkylsilylalkenyl-, alkynyl,
loweralkylsilylalkynyl-, loweralkylsilylaryl-, preferably 4-C6H4SiMe3,
loweralkylsilylbiphenyl-thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
loweralkylalkynyl-, preferably Me3-C≡C-; d) Z- is an anion capable of forming an ionic bond sufficient to form said bis-(aryl) iodonium salt; and
e) each R9 and R10 is the same or different.
Z-, as used herein, is an anion capable of forming an ionic bond with an iodonium cation sufficient to form a salt. Examples of preferred anions include triflate (OSO2CF3), chloride, bromide, iodide, acid sulfate, nitrate, tetrafluoroborate, lactate (CH3CHOHCO2),
sulfonate, organnosulfonate, disulfide, sulfite,
disulfite, thiosulfite, sulfide, hydroxide,
hexafluorophosphate, alkoxide, chlorite, hypochlorite, nitrite, nitrate, azide, triiode, cyanide, hydrazide, perchlorate, haloacetate, preferably fluoroacetate, chloroacetate, bromoacetate, iodoacetate,
fluorochloroacetate, fluorobromoacetate,
chlorobromoacetate, fluorochlorobromoacetate,
loweralkanoate, haloloweralkanoate, preferably
fluoroloweralkanoate, chloroloweralkanoate,
bromoloweralkanoate, iodoloweralkanoate,
fluorochloroaloweralkanoate, fluorobromoloweralkanoate, chlorobromoloweralkanoate, or
fluorochlorobromoloweralkanoate anion.
In another aspect, the invention features a bis-iodonium salt represented by the following formula:
wherein:
a) X is either S or O; or X is NH;
b) n=1; R11a is attached to any one of the number 3 or 4 ring position; or n=2 and each R11a is individually attached to both the number 3 and 4 ring positions and each R11a is the same or different;
and
c) R11a is any one of hydrogen, halogen, loweralkyl, loweralkoxy, haloalkyl-,
cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; d) R11 is any one of a CN-, aryl, preferably 4-phenyl, haloaryl-, preferably 4-C6H4F,
4-C6H4I, loweralkylphenyl-,
haloloweralkylphenyl-, preferably 4-(CF3)C6H4, 3,5-(CF3)2C6H3, halobiphenyl-, preferably 4-C6H4-C6H4-I, alkenyl, loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-, preferably 4-C6H4SiMe3, loweralkylsilylbiphenyl-, thienyl, preferably loweralkylsilylthienyl-, most preferably 2-(trimethylsilyl)thienyl- or
loweralkylalkynyl-, preferably Me3-C≡C-; e) Z- is an anion capable of forming an ionic bond sufficient to form said bis-iodonium salt.
Those skilled in the art will appreciate that the above-mentioned synthetic methods can be adapted to make mono-, di-, other bis-, and higher iodonium compounds, e.g., iodonium compounds which include 3-15 (inclusive) iodonium moieties.
In another aspect, the invention also features a method of inhibiting a PQQ-catalyzed redox reaction, the method including
obtaining an iodonium compound capable of sequestering PQQ;
contacting PQQ with the iodonium compound under conditions capable of forming a PQQ-iodonium complex; and sequestering PQQ in a PQQ-iodonium complex sufficient to inhibit said PQQ-catalyzed redox reaction.
In another aspect the invention also features a method of killing unwanted vegetation, preferably
unwanted kudzu vine, the method including;
obtaining an iodonium compound capable of sequestering PQQ; and
dispersing the iodonium compound on the surface of the unwanted vegetation sufficient to sequester PQQ and kill the vegetation.
In another aspect the invention features a method of killing marine pests, preferably zebra mussels, lamprey eels and starfish, the method including:
obtaining an iodonium compound capable of sequestering PQQ;
dissolving said iodonium compound in an aqueous solvent; and
dispersing said solution over an area subject to marine pest infestation in an amount sufficient to kill the marine pests.
The invention also features a topical fungicide comprising an iodonium compound capable of being
inactivated after skin penetration.
In a related aspect, the invention features a method of inhibiting inflammation in a mammal, preferably a human, the method including:
obtaining an iodonium compound capable of sequestering PQQ;
administering said iodonium compound;
contacting PQQ with said iodonium compound under conditions capable of forming a PQQ-iodonium complex; and sequestering PQQ in a PQQ-iodonium complex sufficient to inhibit said inflammation.
In another aspect, the invention features a method of inhibiting microbial growth on a tissue surface or teeth from a human or veterinary patient, the method including:
providing an iodonium compound exhibiting anti-microbial activity; and
topically applying the iodonium compound to a tissue surface or teeth in an amount sufficient to inhibit growth of susceptible microbes on the tissue surface or teeth. By "microbial growth" is meant the undesired proliferation of organisms such as bacteria, yeast or fungus. By "topically applying" is meant the administration of an iodonium compound to teeth or a tissue surface (either inside or outside the oral cavity) in a pharmaceutically acceptable vehicle. "Susceptible microbes", as used herein, are those organisms, e.g., pathogenic oral bacteria; whose growth is completely inhibited in a test described herein, e.g., the agar dilution method described in part lX (1), below.
In one embodiment, the tissue surface is in the oral cavity (e.g., gums or oral mucosa), preferably in an oral cavity characterized by at least one of dental caries, plaque, gingivitis, periodontitis (e.g.
refracting periodontitis), or gingivitis-induced
inflammation. A particular application of the invention is the inhibitation of microbial growth in
immunodeficient individuals, e.g. HIV-infected patients suffering from the undesired proliferation of oral microbes, e.g., oral fungus accompanying thrush. In another embodiment, the tissue surface is skin outside
the oral cavity, e.g., a skin wound outside the oral cavity. In another embodiment, the tissue surface or teeth have been subjected to dental surgery and the application of the iodonium compound is in the form of an oral rinse, oral irrigant, periodontal pack, or it is topically applied in a pharmaceutically acceptable vehicle. In another embodiment, after topically applying an iodonium compound to a tissue surface or teeth, the iodonium compound is inactivated by applying a non-toxic reducing agent, preferably about 2-4% (w/v) (inclusive) ascorbate or about 2-4% (w/v) (inclusive) sodium
thiosulfate in a pharmaceutically acceptable buffer
(e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)). In another embodiment, either prior to or during topically applying the iodonium compound to a tissue surface or teeth, a boric acid solution,
preferably about 2% (w/v) boric acid in a
pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer at pH 5-9 (inclusive)); is
administered to the tissue surface or teeth in an amount sufficient to enhance the anti-microbial activity of the iodonium compound. Preferably, the boric acid solution is administered immediately prior to the application of the iodonium compound. The enhancement of the anti-microbial activity of an iodonium compound is determined by tests described below, e.g., the agar dilution method described in part lX (1), below.
In a related aspect, the method further includes providing and applying chlorhexidine and an iodonium compound in an amount sufficient to inhibit the growth of susceptible microbes on a tissue surface or teeth.
Preferably, the chlorhexidine and iodonium compound are each applied in amounts of equal anti-microbial activity as determined by methods described herein, e.g., the agar dilution method described in part lX (1), below.
In another related aspect, the method further includes providing and applying two or more iodonium compounds, either by themselves, or in combination with chlorhexidine, where each compound is in an amount of equal anti-microbial activity as defined by methods described herein, e.g., the agar dilution method
described in part IX (1), below.
Brief Description of the Drawings Fig. 1 depicts chemical formulae of PQQ(l), DPI (2), and selected mono-(3,4) and bis(5-8)-iodonium compounds synthesized by triflate-mediated synthetic methods of the invention.
Fig. 2a and Fig. 2b show general schemes for preparing iodonium compounds: Fig. 2a) Scheme 1: bis-iodonium triflate prepared from diiodobenze, and Fig. 2b) Scheme 2: bis-(aryliodonium) thiophene triflate prepared from reaction of an aryl (cyano) iodonium triflate and 2,5-bis(tributyltin)thiophene.
Table 1 shows the inhibition of PQQ-catalyzed redox cycling by selected mono- and bis- iodonium
compounds.
Tables 2 and 3 show the activity of iodonium compounds against oral bacteria.
Tables 4 and 5 show the activity of iodonium compounds against streptococci isolated from patients with refractory peritonitis.
Description of Preferred Embodiments
I. Preparation of Bis-iodonium Triflates -Commercial diiodobenzene (9, Fig. 2) was oxidized to a bis(trifluoroacetate) (10, Fig. 2) by CF3CO3H in 85% yield. CF3CO3H (perfluoroucetic acid) is prepared by mixing 1.5 ml of 80% H2O2 and 20ml trifluoroacetic anhydride. Reaction of (10) with two equivalents of a trimethylsilyl compound RSiMe3 (11, Fig. 2) and
Me3SiOSO2CF3, in CH2Cl2, gave a bis-diiodonium triflate (5, Fig. 2) in 66-97% yields. Examples of bis-iodonium triflate derivatives synthesized from the corresponding trimethylsilyl compound are shown in Fig. 1 (5a-h). The synthesis of diyne bis-iodonium triflates (6a-b, 7) has been described (Stang et al., J. Org. Chem. 57, 1861-1864, (1992)). The bis-iodonium triflate derivative (5h, Fig. 2) was prepared as outlined, except 2,5-bis(trimethylsilyl) thiophene was used as the appropriate trimethylsilyl derivative. Bis-iodonium triflates (8a-b, Fig. 1) were prepared by reacting 2,5-bis(tributyryl) thiophene (13, Fig. 2) with an
aryl(cryano) iodonium triflate (14, Fig. 2).
i) Analysis of Iodonium compounds- Iodonium compounds can be analyzed by HRMS (High Resolution Mass spectroscopy). The expected spectral values of the proposed iodonium compounds can be found below. The spectral values of related iodonium compounds have been published (Watanabe et al., Curr. Ther. Res . 44:896, (1988); Hobara et al., Pharmacology 37:264, (1988);
Nishigori et al., Life Sci . 45:593, (1989); Hamagishi et al., J. Pharmacol . Exp. Ther. 255:980, (1990); Aizenman et al., J. Neurosci 12:2362, (1992); Salisbury et al., Nature 280: 843, (1979); Mah et al., FASEB J., Abstract, 7:A53, (1993); Paz et al., ASBMB/DBC-ACS Joint Meeting, Addendum, Abstract, LB89, (1993); Gardner et al., Society for Neuroscience Abstract, 18:A321.6, (1992); Flückiger
et al., In Principles and Applications of Quinoproteins , Davidson, Ed.; Marcell Dekker, Inc.: New York, pp. 331-341, 1992; Paz et al., J. Biol . Chem . 266:689, (1991)).
II. POO Inhibition Studies with Mono- and Bis-iodonium compounds
PQQ inhibition studies were carried out via a PQQ-catalyzed redox-cycling assay (Flückiger et al., In
Principles and Applications of Quinoproteins, Davidson, Ed.; Marcell Dekker, Inc.: New York, pp. 331-341, 1992; Paz et al., J. Biol . Chem . 266:689, (1991); each
reference herein incorporated by reference) using 13.3 nM PQQ. Several concentrations of each iodonium compound were used in order to determine the IC50. A stock
solution of each iodonium compound was prepared with DMSO and then diluted in water to obtain the desired
concentration. The results of the assay without, and with, various concentrations of an added iodonium
compound are shown in Table I. Each assay was run in parallel in order to control for any non-PQQ catalyzed reduction of 4-nitro blue tetrazolium.
In the redox-cycling assay (picture above), glycine present in large excess is oxidized at pH 10 in air. This chemical reaction is catalyzed by small amounts of PQQ. As reduced PQQ (PQQH2) is generated, it is oxidized by dioxygen to oxidized PQQ (PQQ) and two
superoxide radicals are generated. Superoxide is capable of reducing 4-nitroblue tetrazolium (T+) to visible formazan (TH). In twenty minutes at 37°C, about 2000 redox cycles occur such that nanomolar concentrations of PQQ generate micromolar amounts of visible formazan.
Iodonium compounds that sequester PQQ inhibit the PQQ redox-cycling assay by preventing the reduction of PQQ to PQQH2. Alkynl and aryl monoiodonium triflates
effectively inhibit PQQ-catalyzed redox reactions on a micromolar scale, while bis-iodonium including bis-iodonium triflates, inhibit PQQ-catalyzed reactions on a nanomolar scale.
The results are summarized in Table 1.
Table 1. Iodonium Compounds Sequester PQQ
Experiment Compound IC50*
1 BPI, Ph2I+
10.0μM
2 DPI, 2 1.5μM
3 3a 6.0μM
4 3b 3.0μM
5 3c 19μM
6 3d 437nM
7 4 667nM
8 5a 7nM
9 5b 13nM
10 5c 33nM
11 5d 77nM
12 5e 333nM
13 5f 667nM
14 5g 63nM
15 5h 36nM
16 6a 1.3μM
17 6b 667μM
18 7 2.0μM
19 8a 29nM
20 8b 13nM using 13.3nM PQQ.
The data in Table 1 indicate that bis-iodonium compounds are capable of sequestering PQQ, thereby
inhibiting electron transfer in the redox cycling assay. Bis-iodonium compounds are more effective PQQ
sequestering agents than mono-iodonium compounds. For example, Table 1 shows that redox-cycling assay
inhibition by alkynl mono-iodonium compounds (3a-d) is comparable to inhibition of PQQ by Ph2I+ (BPI) and DPI.
However, the bis-iodonium compounds (5a-h, 6a-b, 7, 8a-b, in Fig. 1) are the most effective in inhibiting redox-cycling. The data indicate that bis-iodonium salts 5a-c, 8a-b are the most effective at sequestering PQQ and
inhibiting electron transfer in the redox cycling assay. Compounds 5a-c, 8a-b are 100-1000X better than mono-iodonium compounds at sequestering PQQ and inhibiting electron transfer in the redox-cyciing assay.
PQQ-catalyzed redox-cycling reactions are
essential to maintain life and require the transfer of electrons down an electrochemical gradient from one
component of the redox cycle to the next (see above). NAD- or FAD-catalyzed electron transport in cells and cell organelles such as mitochondria, require electron
transfer from one component of an electron transport chain to the next component down an electrochemical gradient. Electron transfer reactions also occur in plant chloroplasts and bacteria (see Stryer, Biochemistry 3rd Ed. pp. 397-407; Alberts, et al. The Cell pp. 341-387; both references herein incorporated by reference). Two bis-iodonium compounds (5a, 5b) strongly inhibit NAD-catalyzed electron transport in the mitochondria (see Paz et al., ASBMB/DBC-ACS Joint Meeting, Addendum, Abstract LB80, (1993)). The inhibition of mitochondrial electron transport by bis-iodonium compounds is reversed by the addition of PQQ. Those skilled in the art of
biochemistry would know from these results that bis-
iodonium compounds would also inhibit electron transport in a wide range of bacteria, plants, fungi, and animals.
Given that DPI is selective for muscle cells, the chemical moieties present in iodonium compounds described above afford selective cell permeability to these
compounds. Given that iodonium compounds are capable of selective cell permeability and are capable of
sequestering PQQ, thereby inhibiting redox-cycling reactions such as NAD- or FAD-dependent electron
transport, iodonium compounds preferably bis-iodonium compounds, are useful as effective and selective
inhibitors of electron transfer reactions involving PQQ. Such iodonium compounds inhibit in vitro and in vivo enzymatic reactions involving electron transfer in a wide variety of bacteria, fungi, plants, and animals, thereby serving as effective biocidal agents. The in vitro redox-cycling assay described above can be used to screen iodonium compounds of the invention for the ability to sequester PQQ and inhibit redox-cycling. Iodonium compounds that sequester PQQ and inhibit redox-cycling in vitro will serve as effective biocidal agents.
III. Experimental Methods. Melting points of iodonium compounds were obtained with a Mel-Temp
capillary melting point apparatus. Infrared spectra were recorded on a Mattson FT-IR spectrophotometer. NMR spectra were recorded on a Varian XL 300 spectrometer at 300 MHz (1H NMR), 75 MHz (13C NMR) , 282 MHz (19F NMR). Chemical shifts for 1H and 13C NMR are reported in parts per million (PPM) relative to internal tetramethylsilane or the proton resonance due to the residual in protons in the deuterated NMR solvent; the chemical shifts for 19F NMR are relative to external CFCl3 Mass spectra were obtained with a VG Micromass 7050E double focusing high resolution mass spectrometer with the VG data system 2000
under positive ion fast atom bombardment (FAB) conditions at 8 keV.3-Nitrobenzyl alcohol was used as a matrix in CH2Cl2 or CHCl3 as solvent, polypropylene glycol was used as a reference for peak matching. Microanalysis were performed by Atlantic Microlab Inc., Norcross, Georgia.
IV. Materials. All commercial reagents were ACS reagent grade and used without further purification.
Aryl (cyano) iodonium triflates (14, Fig. 2) were prepared from bis(trifluoroacetoxy)iodoarenes,
trimethylsilyltriflate and cyanotrimethylsilane (Zhdankin et al., Tetrahedron Letters 34:6853, (1993)). Iodonium compounds 3, 4, 6 and 7 in Fig. 1 were prepared by published methods (Bachi et al., J. Org. Chem . 56:3912, (1991); Stang et al., J. Heterocyclic . Chem . 29:815, (1992); Stang et al., J. Org. Chem . , 57:1861, (1992); Stang et al., J. Am . Chem . Soc . 114:4411, (1992)). All solvents used were dried by distillation over CaH2. The reaction flasks were flame-dried and flushed with
nitrogen.
p-[Tetra(trifluroracetoxy)diiodo]benzene: (10 in Fig. 2a) p-Diiodobenzene 9 (3.3 g, 10 mmol) was added by small portions during 30 min to a stirred mixture of CF3CO3H [prepared from trifluoroacetic anhydride (10 ml, 71 mmol) and 80% hydrogen peroxide (2 ml, 47 mmol) by known procedure. An additional oxidizing agent can be prepared by mixing similar amounts of peracetic acid and hydrogen peroxide.] The reaction mixture was stirred for 0.5 h at -78° C, then 2 h at -20° C and left overnight at room temperature. Concentration of the resulting clear solution and crystallization of the product by addition of ether afforded analytically pure 10 as a white
microcrystalline solid, yield 6.64 g (85%); mp 195-197° C (decomp.). IR (CCl4, cm-1): 3084, 3061 (C6H4), 1664, 1146, 982 (all CF3CO2). 1H NMR ( δ , CF3CO2H/CDCl3 1/10): 8.43 (s, C6H4). 19F NMR (δ , CF3CO2H/CDCl3 1/10): -78.9
(s, CF3CO2) . 13C{1H} NMR (δ, CF3CO2H/CDCl3 1/10) : 118.7 (q, CF3); 126.0 (s, CipsoAr) ; 137.9 (s, CHAr) , 162.4 (q,
C=0) . Anal. Calcd for C14H4I2O8F12: C, 21.50; H, 0.52.
Found C, 21.16; H, 0.78.
V. Detailed Procedure for the Preparation of
(p-Phenylene) bisiodonium Triflates (5; Fig. 2): To a stirred solution of 10 (0.78 g, 1 mmol) in
CH2Cl2 (20 ml) the corresponding silylated arene 11 (2.5-3 mmol) and Me3SiOTf 12 (0.5 ml, 2.5 mmol) were added at -78°C under N2. The reaction mixture was allowed to warm to room temperature and additionally stirred for 3-5 h.
Colorless microcrystalline products 5a-f (Fig.1)
precipitated in analytically pure form,
i) Physical and Spectral Data:
5a: Yield 0.05 g (6%); mp 252-260° C (decomp.) IR
(CCl4, cm-1): 3086 (Ar), 1245, 1167, 1028 (all CF3SO3).
1H NMR (5, d6-DMSO) : = 7.25 (dd, 4H, J=7.0 Hz), 8.12 (m,
8H); 19F NMR (δ, d6-DMSO) : -78.5 (s, CF3SO3), -106.1 (s,
ArF). 13C{1H} NMR (δ , d6-DMSO); 121.3 (q, J = 318 Hz, CF3SO3~); 120.1, 120.4, 137.3, 138.4, 138.7, 139.2 (all
Ar).
5b: Yield 0.7 g (90%); mp 280-290° C (decomp.). 5c: Yield 0.95 g (92%); mp 270-275° C (decomp.).
IR (CCl4, cm-1): 3082 (Ar), 1265, 1170, 1024 (all CF3CO3). 1H NMR (δ, d6-DMSO) : 7.82 (d, 4H, J = 7.3 Hz), 7.87 (d,
4H, J = 7.4 Hz), 8.12 (s, 4H). 19F NMR (δ , dg-DMSO): - 77.8 (s, CF3SO3) . 13C{1H} NMR (δ, d6-DMSO) : δ = 121.3 (q,
J = 318 Hz, CF3SO3~) ; 96.5, 120.1, 120.5, 138.4, 138.9,
141.2 (all s, Ar). HRMS (FAB) for C19H12SI4O3F3 [M]TfO-]+ calcd 88.4663334, found 884.661143. Anal Calcd for
C20H12I4O6F6S6: C, 23.23; H, 1.17; I, 49.09. Found: C,
32.24; H, 1.69; I, 42.61.
5d: Yield 0.79 g (66%); mp 275-278° C (decomp.).
IR (CCl4, cm-1): 3082 (Ar), 1247, 1168, 1026 (all CF3SO3). 1H NMR (δ, d6-DMSO) : 7.36 (d, 4H, J = 7.5 Hz), 7.70 (d,
4H, J = 7.6 Hz), 7.80 (d, 4H, J = 7.5 Hz), 8.12 (s, 4H),
8.14 (d, 4H, J = 7.5 Hz) . 19F NMR (δ, d6-DMSO) : -78.4 (s, CF3SO3) . 13C{1H} NMR ( δ , d6-DMSO) : 121.0 (q, J = 318 Hz, CF3SO3~) ; 95.2, 120.3, 120.6, 131.4, 136.5, 136.8, 136.9, 137.5, 138.4, 138.6 (all Ar) . HRMS (FAB) for C31H20SI4O3F3 [M-TfO-]+ calcd 1036.725934, found
1036.723128. Anal. Calcd for C32H20I4O6F6S2: C, 32.40; H, 1.70; I, 42.79. Found: C, 32.24; H, 1.69; I, 42.61.
5e: Yield 0.9 g (97%) ; mp 255-257° C (decomp.) . 5f: Yield 0.7 g (85%) ; mp 183-185° C (decomp.) . 5g: Yield 0.93 g (86%) ; mp 256-258° C (decomp.) .
IR (CC14, cm-1) : 3082 (Ar) , 2957 (Me3Si) , 1245, 1167, 1027 (all CF3SO3) . 1H NMR (δ, d6-DMSO) : 0.21 (s, 18H) , 7.62 (M, 8H) , 7.74 (d, 4H, J = 7.6 Hz) , 8.12 (s, 4H) , 8.15 (d, 4H, J = 7.5 Hz) . 19F NMR (δ , D6-DMSO) : -78.2 (s, CF3SO3) . 13C{1H} NMR (δ, d6-DMSO) : -1.5 (s) , 121.0 (q, J = 318 Hz, CF3SO3~) ; 120.1, 120.7, 131.4, 136.5, 136.8, 136.9, 137.5, 138.4, 138.6, 141.5 (all Ar) . HRMS (FAB) for
C37H38SSi2I2O3F3 [M-TfO-]+ calcd 929.011939, found
929.012254.
5h: Yield 0.8 g (85%) ; mp 225-230° C (decomp.) .
IR (CCl4, cm-1) : 3075, 2965, 1474, 1384, 1282, 1235, 1165, 1026, 911. 1H NMR (δ, CD3CN) : 8.03 (s, 4H) , 7.90 (d, J = 8.0 Hz, 2H) , 7.24 (d, J = 8.0 Hz, 4H) , 0.21 (s, 18H, 2Me3Si) . 19F NMR (δ, CD3CN) : -78.3 (s, CF3SO3) . HRMS (FAB) for C21H26S3Si2I2O3F3 [M-TfO-]+ calcd 788.862184, found 788.861207.
VI. Reaction of 2.5-bis (tributyltin) thiophene (13. Fig. 2b) with aryl (cyano) iodonium triflate (14. Fig. 2b).
To a stirred solution of reagent 14 (1 mmol) a solution of the appropriate tributyltin derivative 13 (1- 1.5 equivalents) in CH2Cl2 (15 ml) was added at -40° C.
The mixture was warmed to room temperature and stirred until the formation of a clear solution. The products
(8, Figs. 1, 2b) were precipitated from the reaction mixture by the addition of dry hexane (20-30 ml). The microcrystalline iodonium triflate salt was filtered under nitrogen, washed with dry hexane (30 ml) and dried in vacuo. Analytically pure materials were obtained by recrystallization from a concentrated solution of the iodonium salt in CH2Cl2 by addition of hexane and ether. Other organotin derivatives, for example
methylethynyltributytin and phenyltributyltin, can be substituted for 13 (Fig. 2b) in order to obtain the corresponding bis(aryliodonium) theophene.
i) Physical and Spectral Data
8a: Yield 0.39 g (49%), mp 193-194° C (decomp.). IR (CCl4, cm-1): 3097, 3066, 1241, 1159, 1023. 1H NMR (δ, d6-DMSO/CD3CN) : 7.55 (t, J = 8.0 Hz, 4H), 7.71 (t, J = 8.0 Hz, 2H), 7.83 (s, 2H), 8.19 (d, J = 8.0 Hz, 4H). 19F NMR (δ , d6-DMSO/CD3CN) : -78.74 (s, CF3SO3~). 13C{1H} NMR (6, d6-DMSO/CD3CN) : 111.0, 119.4, 121.2 (q, J = 320.7 Hz, CF3SO3~), 132.3, 132.9, 135.1, 140.9. Anal. Calcd for C18H12I2O6F6S3: C, 27.43; H, 1.53; S, 12.20. Found: C, 27.35; H. 1.56; S, 12.12.
8b: Yield 0.21 g (25%), mp 170° C (dec). IR
(CCl4, cm-1): 3098, 1575, 1246, 1170, 1027 cm-1; 1H NMR ( δ , CD3CN) : 8.15 (dd, 4H), 7.85 (s, 2H), 7.3 (dd, 4H); 19F NMR (δ, CD3CN) : -78.1 (CF3SO3~), -105.0 (FC6H4). 13C NMR (δ, CD3CN) : 162.5 (d), 138.7, 136.3, 136.2, 121,0 (q, CF3SO3), 117.7, 110.5. FAB HRMS m/z 674.804664 [M-CF3SO3-]+, calcd for C17H10I2S2F5O3: 675.807858.
VII. Iodonium Salts as Biocidal Agents
Iodonium compounds of the invention are useful as herbicides which kill unwanted vegetation, e.g., the kudzu vine; as insecticides which kill insects, e.g., the gypsy moth; and as agents which kill marine pests, e.g., zebra mussels, starfish, and lamprey eels. For such uses, an iodonium triflate or other iodonium salt of the invention can be dispersed on an inert finely divided solid (e.g., silica) and employed as a dust. Such a mixture can be used directly on plants or insects.
Alternatively, an iodonium triflate or other iodonium salt of the invention can be employed as a spray or emulsion by dissolving in water, preferably a solution of 90% by weight water and 10% by weight dimethylsulfoxide (DMSO) or 10% by weight acetonitrile or 10% by weight dimethylformanide. Preferred compositions contain from 0.0001% to 50% by weight of an iodonium triflate or other iodonium salt of the invention.
i) Use as a topical fungicide - An iodonium triflate or other iodonium salt of the invention, can be delivered in a pharmaceutically acceptable carrier to a skin surface subject to fungal infection. Suitable carriers include water, oils such as mineral oils, soybean oil and the like, creams or gels comprising glycerol and/or potassium, ammonium or sodium stearate, and water. Preferably an iodonium triflate or other iodonium salt of the invention can be used in a carrier at 0.05% by weight. Examples of other pharmaceutically acceptable carriers for topical administration can be found in Remington 's Pharmaceutical Sciences, Mack
Publishing Co.: Easton, PA, 1980.
VIII. Iodonium Compounds as Anti-Inflammatory Agents
Macrophages and neutrophils mediate inflammatory reactions associated with trauma, pulmonary emphysema, cystic fibrosis, bronchitis, psoriasis, arthritis, and
rheumatoid arthritis, among other inflammatory diseases. Tissue destruction by macrophages and neutrophils has been extensively reviewed (Weiss, S.J. N . Engl . J. Med . 320, 365 (1989); Lehrer, R.I. et al. Ann. Intern . Med . 109, 127, (1988); Malech, H.L. et al. Ann. Intern . Med . 317, 687, (1987)). Both cell types expose phagocytosed cells and/or tissue to free radical species such as superoxide (O2-), hydroxyl radical and hypochlorite.
Macrophages and neutrophils produce free radical species by using known redox-cycling reactions. Without wishing to bind ourselves to any particular theory, it is
proposed that free radical generation involves PQQ. Given that iodonium compounds of the invention inhibit redox-cycling by sequestering PQQ, iodonium compounds modulate the toxicity of free radical species produced by
macrophages and neutrophils which is associated with inflammation.
I. Testing Iodonium Compounds - Methods of isolating neutrophils and in vitro and in vivo model systems for testing the activity of agents that inhibit free radical formation by neutrophils are well known (reviewed in Weiss, S.J. N . Engl . J. Med . 320, 365
(1989); Lehrer, R.I. et al. Ann . Intern . Med . 109, 127, (1988); Malech, H.L. et al. Ann . Intern . Med . 317, 687, (1987)). In general, an iodonium compound of the
invention can be dissolved in water, preferably water with 10% DMSO or other suitable solvent and added to a an in vitro model system comprising neutrophils in order to see if the production of damaging free radicals has been reduced. Preferably, an iodonium compound is at a
concentration of at least one microgram per ml in these systems. In vivo model systems for testing the activity of agents that inhibit neutrophils or macrophage free radical generation are also known in the art, for example
rodent models are known and can be used to test iodonium compounds of the invention for anti-inflammatory activity in vivo.
IX. Iodonium Compounds Are Anti-Microbial Agents Suitable For Topical Application
It is an object of the invention to use one or more iodonium compounds, e.g., mono-, di-, bis-, and higher iodonium compounds, e.g., compounds which include 3-15 (inclusive) iodonium moieties; whenever
chlorhexidine administration is indicated, but with superior results. Like chlorhexidine, iodonium compounds are anti-microbial agents which can alleviate juvenile and adult periodontal diseases such as gingivitis, periodontitis (e.g., refractory peritontitis),
gingivitis-induced inflammation, oral thrush, and acute necrotizing gingivitis. Like chlorhexidine, iodonium compounds are also effective anti-microbial agents for use in general or preoperative skin cleaning,
preoperative showering or bathing, wound cleaning, or as a sterilizing agent for the treatment of dental caries.
However unlike chlorhexidine, iodonium compounds can be inactivated after use by briefly applying a non-toxic reducing agent. The ability to inactivate an iodonium compound after use reduces the potential for teeth or mouth tissue damage (e.g., teeth staining). Examples of non-toxic reducing agents suitable for use include 2-4% (w/v) sodium ascorbate or 2-4% sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer at pH 5-9 (inclusive)). Other pharmaceutically acceptable salts of ascorbate and thiosulfate can also be used, e.g., potassium ascorbate and potassium thiosulfate. Other useful non-toxic reducing agents can be identified by combining a molar excess (e.g., a 1.5 fold molar excess) of the reducing
agent with a particular iodonium compound and evaluating the anti-microbial activity of the treated iodonium compound in the agar dilution method described in part IX (1), below. Generally, an acceptable non-toxic reducing agent will eliminate the anti-microbial activity of the iodonium compound. The anti-microbial activity of an iodonium compound can be enhanced by administering, either prior to or during the topical application of the iodonium compound, a 2-4% (w/v) (inclusive) boric acid solution in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate at pH 5-9 (inclusive)).
Preferably, the boric acid solution is administered immediately prior to the application of the iodonium compound. The enhancement of the anti-microbial activity of an iodonium compound is at least 1.5 fold and can be determined by tests described herein, e.g., the agar dilution method described in part lX (1), below.
An iodonium compound, e.g., a mono-, di-, bis-, or higher iodonium compound, e.g., a compound including 3-15 (inclusive) iodonium moieties, can be used with one or more other iodonium compounds or optionally, combined with chlorhexidine, each compound in amounts of equal anti-microbial activity (determined by methods described below, e.g., the agar dilution method described in part IX (1), below). The combination of one or more iodonium compounds or optionally, chlorhexidine, will reduce the danger of selecting resistant oral flora. An iodonium compound, either alone, with one or more other iodonium compounds, or optionally combined with chlorhexidine, can also be used in: 1) general or preoperative skin cleaning
(e.g., surgical scrub); 2) preoperative showering or bathing; 3) wound cleaning; or 4) as a sterilizing agent for the treatment of dental caries, e.g., to sterilize a cavity prior to performing dental restoration,
e.g., insertion of amalgam to fill a cavity.
1. Iodonium compounds Inhibit Oral Bacteria
Growth
A) Agar Dilution Method: Iodonium compounds were tested for anti-microbial activity against reference strains of oral bacteria. These reference strains included 48 subgingival species (Tables 2 and 3) and 26 strains of streptococci isolated from patients with refractory periodontitis (Tables 3 and 4). By
"refractory" is meant that the periodontitis was
resistant to conventional intervention, e.g., antibiotic treatment; oral antiseptic treatment, including
chlorhexidine use. Several of these bacteral strains are known oral pathogens, e.g. Porphyromonas gingivitis . The Minimum inhibitory Concentration (i.e. MIC) was
independently determined for bis-iodonium compounds 6a, 8a, and 8b (see Fig. 1). The MIC was defined as the minimum concentration of an iodonium compound necessary to completely inhibit the growth of a reference strain of bacteria.
1) Preparation of Agar Medium
The composition of the agar medium is disclosed below:
Agar medium was sterilized in individual test tubes (1 test tube per Petri plate) by autoclaving at 121°C for 15 min. The sterilized agar medium was
subsequently cooled in a 50°C water bath. The volume in each tube was adjusted with water so that the final volume approximate 40 ml when the filter-sterilized bis-iodonium compounds were added to the agar medium.
2) Preparation of test media
Bis-iodonium compounds 6a, 8a, and 8b (see Fig. 1) were each dissolved in 5 ml of dimethyl sulfoxide, then distilled water was added to adjust the final
concentration of bis-iodonium compound (in 40 mls of agar medium) to 2μg/ml, 4 μg/ml, 8 μg/ml, 16 μg/ml, 32μg/ml or 64 μg/ml. As a control, a solution was prepared without any added bis-iodonium compound. Each solution was subsequently filter sterilized by passage through a 0.22 μm Nalgene filter. After addition of control or bis-iodonium compound containing solutions into about 40 mls agar medium, the agar medium was aseptically dispensed into plastic microtiter dishes. The agar medium was allowed to set overnight.
3) Preparation of bacterial inocula
Individual bacterial species were maintained on blood agar plates under an atmosphere of 80% N2, 10% H2 and 10% CO2 at 35°C for 3 days. Bacterial inocula was aseptically harvested from each plate and suspended in 1 ml of sterile mycoplasma broth (Baltimore Biological Labratories). Each bacterial suspension was adjusted to an optical density approximating a MacFarland 0.5
standard (see generally, Manual of Microbiological
Methods , American Society for Microbiology, McGraw-Hill, N.Y. (1957)).
4) Inoculation of test media
100 μl of each bacterial strain suspension was placed in the microtiter plate containing either control agar medium or agar medium with 2 μg/ml, 4 μg/ml, 8 μg/ml, 16 μg/ml, 32μg/ml or 64 μg/ml of a bis-iodonium compound. Because of the large number of individual
bacterial species tested, an MIC 2000 inoculator was used to transfer 1.5 μl of each inoculum to the surface of a microtiter plates. Control plates were inoculated at the beginning and end of the series of inoculations to verify aseptic experimental conditions. These plates were used to indicate that the inoculum was present and viable throughout the series. This was confirmed for all species.
5) Results
Agar plates were incubated under an atmosphere of 80% N2, 10% H2 and 10% CO2 at 35°C. The MIC for each iodonium compound and reference strain was determined after an incubation period of 5 days. The data are presented in Tables 2, 3, 4, 5, below.
Tables 2, 3, 4 and 5 show that iodonium compounds inhibit the growth of a wide variety of bacteria; several iodonium compounds exhibit anti-microbial activity which is superior to that of chlorhexidine. For example, table 2 shows that iodonium compounds inhibit the growth of several subgingival bacterial species below 64 μg/ml.
Oral bacteria such as B . forsythus, C . rectus, F .
nucleatum subspecies, P . gingivalis, P . intermedia, P. nigrescens and P. micros, were each sensitive to compound 8b ( a bis-iodonium compound) at low levels (≤ 16 μg/ml). P. intermedia and P. nigrescens were especially sensitive to iodonium compounds 6a and 8b. Generally, each of these bacteria are extremely difficult to eliminate from the oral cavity and each are suspected oral pathogens. Table 4 shows that iodonium compounds inhibit the growth of streptococci isolated from patients with refractory periodontitis. For example, strain HA45 was inhibited by iodonium compounds 6a, 8a, and 8b. Tables 3 and 5 point out that several iodonium compounds exhibit a lower MIC (i.e. better anti-microbial activity) than chlorhexidine. For example, compounds 4a, 5b and 4 (a mono-iodonium compound) inhibit the growth of C. concisus at levels 2-4 fold lower than chlorhexidine. The data indicate that mono-, di-, bi-, and higher iodonium compounds, e.g., compounds including 3-15 (inclusive) iodonium moieties, can be used to inhibit the growth of a variety of oral bacteria on a tissue surface or teeth from a human or veterinary patient.
B) Additional tests: Iodonium compounds can be tested for anti-microbial activity by other well-known methods. Such tests are useful for evaluating the anti-microbial activity of an iodonium compound. For example, a paper disc can be impregnated with an iodonium compound and placed on the surface of an agar plate which includes a lawn of any gram-negative or gram-positive bacteria,
for example, any bacteria of the genus streptococci (gram negative) or staphylococci (gram positive). Such
bacteria can include pathogenic bacteria found inside the oral cavity or outside the oral cavity, e.g., on a skin surface. The concentration of a particular Iodonium compound in the paper disc can be varied by serial dilution in order to determine the MIC. Standard
criteria for interpreting paper disc tests have been published (Bauer et al., Am. J. Clin. Path. 45, 493-496 (1966)). The method of Hennessey can also be used to determine the anti-microbial activity of an iodonium compound against streptococci or staphylococci strains (J. Periodont. Res. 8, 61, (1973)).
The anti-fungal activity of an iodonium compound against opportunistic infections of the oral cavity, for example, thrush fungus (i.e. Candida albicans) can be examined by the method of Budtz-Jorgensen E. and Loe, H. (Scand. Dent. J. Dent. Res. 80, 457 (1972). In another test, anti-plaque activity of an iodonium compound can be evaluated by topically applying (e.g. rinsing) about 10 ml of a 0.2% (w/v) solution of the iodonium compound, followed by an examination of plague deposits or salivary bacteria (Loe, H. and Schiott C.R., J. Periodont. Res 5, 79 (1970); Schiott, C.R. et al. J. Periodont Res. 5, 84 (1970)).
In any above test method, chlorhexidine can be coadministered (at a concentration giving equivalent anti-microbial activity) with an iodonium compound in order to detect synergistic anti-microbial effects between
chlorhexidine and the iodonium compound.
C) Administration: An iodonium compound which inhibits the growth of susceptible microbes by any above-described test (e.g., compounds 6a, 8a, 3c, 4a, 5b, 4 and 8b) can be used as an oral rinsing agent, oral irrigating agent, subgingival irrigating agent, or periodontal pack.
For oral use, an iodonium salt (e.g., the gluconate salt of compounds 6a, 8a or 8b) can be combined with water, about 10% alcohol, a sorbitan stearate, and a flavoring agent. Generally, the effective final concentration of an iodonium compound is at least 1 μg/ml (between 0.001% and 2% w/v (inclusive)). If desired, administration of an iodonium compound is followed by applying a non-toxic reducing agent, e.g. about 2-4% (w/v) sodium ascorbate or about 2-4% (w/v) sodium thiosulfate in a pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)) in order to inactivate (i.e. chemically reduce) the compound. The non-toxic reducing agent is desirably in molar excess with respect to the applied iodonium compound (at least 1.5-fold molar excess). If desired, the activity of an iodonium
compound can be enhanced by topically applying (either before or during application of the iodonium compound) about 2% boric acid in pharmaceutically acceptable buffer (e.g., phosphate or bicarbonate buffer, each at pH 5-9 (inclusive)). Generally, in order to inactivate or enhance iodonium compound activity, a non-toxic reducing agent or boric acid solution (respectively) is applied for at least 1 minute, followed by rinsing with a
pharmaceutically acceptable buffer or water. For
example, an oral rinse which includes an iodonium
compound can be inactivated by rinsing 3 times (about 30 seconds each) with a 2% (w/v) ascorbate solution, followed by one (about 10 second) water rinse.
For use as an agent which inhibits the growth of susceptible microbes outside the oral cavity, e.g., use as a skin cleanser (e.g., surgical scrub), preoperative showering or bathing, or wound cleaner; an iodonium salt (e.g., the gluconate salt of compounds 6a, 8a or 8b) can be dissolved in 4% isopropyl alcohol at a final
concentration of at least 1 μg/ml or 0.1%-5% (w/v)
(inclusive) in a pharmaceutically acceptable carrier (vehicle) which includes a detergent and/or emollient. As discussed previously, the anti-microbial activity of the applied iodonium compound can be inhibited or
enhanced, if desired. Chlorhexidine or another
antiseptic may be optionally added in an amount of equal anti-microbial activity (determined by methods described herein, e.g., the agar dilution method described in part lX, (1), above).
Examples of well-known pharmaceutically acceptable vehicles for oral or external use can be found in
Remington's Pharmaceutical Sciences (Mack Pub. Co.,
Easton, PA, 1980).
All publications and patent applications mentioned in the specification are indicative of the level of skill of those in the art to which this invention pertains.
All publications and patent applications are incorporated herein by reference to the same extent as if each
individual publication or patent application were
specifically and individually stated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one skilled in the art will easily ascertain that certain changes and modifications can be practiced without departing from the spirit and scope of the appended claims.
Claims
1. A method of making a bis-(aryl)iodonium triflate, said method comprising:
wherein:
a) Ar is any one of phenyl, biphenyl, or an aryl optionally substituted by one or more R1 groups independently selected from any one of a halogen, loweralkyl, loweralkoxy,
haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; combining said diiodoarene with an oxidizing agent capable of forming an oxidized iodoarene; reacting said oxidized diiodoarene with a loweralkylsilyl compound of the general formula:
(R2)3Si-R3
wherein:
a) R2 is any one of methyl, ethyl, propyl, iso-propyl, butyl, and each R2 is the same or different; b) R3 is any one of a CN-, aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-, loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl, loweralkylsilylthienyl-, or
loweralkylalkynyl-;
and
a loweralkylsilyltriflate of the general formula
(R4)3-SiOSO2CF3 wherein:
a) R4 is any one of methyl, ethyl, propyl, iso-propyl, butyl, and each R4 is the same or different; under conditions capable of forming an bis-(aryl) iodonium triflate of the following general formula:
a) each R1 and R3 is the same or different; and
b) each R1 and R3 is as defined above.
2. The method of claim 1, wherein said
diiodoarene is of the following general formula:
a) n=1; and R4 is attached to any one of an ortho, or meta ring position; or b) n=2, 3, or 4 and each R4 is individually attached to two or more ortho or meta ring positions and each R1 is the same or
different;
and
c) R4 is any one of a hydrogen, loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group.
3. A method of making an organo-substituted iodonium triflate, said method comprising
obtaining an organotin compound of the general formula:
R6-Sn(R5)3
wherein:
a) R5 is any one of methyl, ethyl, propyl, iso-propyl, butyl, and each R5 is the same or different; b) R6 is any one of an aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-, loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl,
loweralkylsilylthienyl- or
loweralkylalkynyl-; combining said organotin compound with an iodonium trifate of the following general formula:
R7-I+-CN[OSO2CF3]-
wherein:
a) R7 is any one of an aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl,
loweralkylsilylthienyl-, or
loweralkylalkynyl-; under conditions capable of forming an organo-substituted iodonium triflate of the following general formula:
R6-I+-R7 [OSO2CF3]-
wherein:
a) each R6 and R7 is the same or different; and
b) each R6 and R7 is as defined above.
4. A method of making an organo-substituted bis-iodonium triflate, said method comprising
obtaining an organostannane of the general formula:
wherein:
a) X is either S or O; or X is NH; b) R8a is any one of is any one of methyl, ethyl, propyl, iso-propyl, butyl, and each R8a is the same or different; c) n=1; and R9a is attached to any one of the number 3 or 4 ring positions; or n=2 and each R9a is individually attached to both the number 3 and 4 ring positions and each R9a is the same or different; d) R9a is any one of hydrogen, halogen, loweralkyl, loweralkoxy, haloalkyl-,
cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; and combining said organostannane with an iodonium triflate of the general formula: R8-I+-CN[OSO2CF3]-
wherein:
a) R8 is any one of a aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl,
loweralkylsilylthienyl-, or
loweralkylalkynyl-;
under conditions capable of forming an organo-substituted bis-iodonium triflate of the following general formula:
wherein:
a) X is either S or O; or X is NH; b) each R8 and R9a is the same or different; and
c) each R8 and R9a is as defined above.
wherein:
a) Ar is any one of a phenyl, biphenyl, or an aryl group optionally substituted by one or more R9 groups independently selected from any one of loweralkyl, loweralkoxy,
haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; b) R9 is any one of a loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; c) R10 is any one of a CN-, aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl, loweralkylsilylalkynyl-,
loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl, loweralkylsilylthienyl-, or
loweralkylalkynyl-;
d) Z- is an anion capable of forming an ionic bond sufficient to form said bis-(aryl) iodonium salt; and e) each R9 and R10 is the same or different.
6. The bis-(aryl) iodonium salt of claim 5, said Ar group being phenyl.
7. A bis-iodonium salt represented by the following formula:
a) X is either S or O; or X is NH; b) n=1; R11a is attached to any one of the number 3 or 4 ring position; or n=2 and each R11a is individually attached to both the number 3 and 4 ring positions and each R11a is the same or different; c) R11a is any one of hydrogen, halogen, loweralkyl, loweralkoxy, haloalkyl-, cycloalkyl, aryl, heteroatom substituted aryl, aryloxy, or heterocyclic group; d) R11 is any one of a CN-, aryl, haloaryl-, loweralkylphenyl-, haloloweralkylphenyl-, halobiphenyl-, alkenyl,
loweralkylsilylalkenyl-, alkynyl,
loweralkylsilylalkynyl-,
loweralkylsilylaryl-,
loweralkylsilylbiphenyl-, thienyl,
loweralkylsilylthienyl-, or
loweralkylalkynyl-; and e) Z- is an anion capable of forming an ionic bond sufficient to form said bis-iodonium salt.
8. The method of any one of claims 1, 2 or 5 wherein R1 is any one of methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, sec-butyl, or tert-butyl.
9. The method of any one of claims 1, 2 or 5 wherein R1 is a heteroatom substituted aryl group, selected from the group consisting of any one of nitro, nitroso, cyano, carboxyl, aldehydo, hydoxy, and
loweralkoxy.
10. The method of any one of claims 1-5, wherein Ar or R3, or both are selected from the group consisting of phenyl, benzyl, tolyl, cumyl, naphthyl, or substituted napthyl, biphenyl, anthracenyl, phenanthrenyl, azulenyl, and pyrenyl group.
11. The method of claim 10, said substituted napthyl group being either a haloalkyl or cycloalkyl substituted napthyl group.
12. The method of any one of claims 1, 2 or 5, wherein R1 any one of a fluoromethyl, chloromethyl, bromomethyl, fluorochloromethyl, fluorobromomethyl, chlorobromomethyl, or fluorochlorobromomethyl group.
13. The method of claim 11, wherein R1 any one of a fluoromethyl, chloromethyl, bromomethyl,
fluorochloromethyl, fluorobromomethyl, chlorobromomethyl, or fluorochlorobromomethyl group.
14. The method of any one of claims 1, 2 or 5, wherein R1 is any one of cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl group.
15. The method of claim 11, wherein R1 is any one of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl group.
16. The method of any one of claims 1, 2, or 5 wherein R1 is any one of methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, or tert-butoxy group.
17. The method of claim 9, wherein R1 is any one of a methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, or tert-butoxy substituted aryl group.
18. The method of any one of claims 1, 2 or 5, wherein R1 is heterocyclic group being any one of a pyridiyl, furyl, thienyl, or pyrrolyl group.
19. The method of any one of claims 1, 2 , or 5, wherein R1 is either phenoxy or benzoxy.
20. The method of claim 2, said diiodoarene being 1,4-diiodobenzene.
21. The method of any one of claims 1-5, wherein
R3 is 4-C6H4F, or 4-C6H4I.
22. The method of any one of claims 1-5, wherein
R3 is 4-C6H4SiMe3.
23. The method of any one of claims 1-5, wherein R3 is 4-C6H4-C6H4SiMe3.
24. The method of any one of claims 1-5, wherein
R3 is 4-C6H4-C6H4I.
25. The method of any one of claims 1-5, wherein
R3 is 4-C≡CSiMe3.
26. The method of any one of claims 1-5, wherein R3 is a 2-(trimethylsilyl)thienyl group.
27. The method of any one of claims 1-5, wherein R3 is either 3,5-(CF3)2C6H3 or 4-(CF3)C6H4.
28. The method of claim 1 or 2, said oxidizing agent capable of forming an oxidized diodoarene being either pertrifluoroacetic acid or peracetic acid.
29. The method of claim 1 or 2, said
loweralkylsilyltriflate group being
trimethylsilyltriflate.
30. The method of claim 3, wherein R5 is butyl.
31. The method of claim 1 or 2, wherein R2 is butyl.
32. A method of inhibiting a PQQ-catalyzed redox reaction, said method comprising
obtaining an iodonium compound capable of sequestering PQQ;
administering said iodonium compound;
contacting PQQ with said iodonium compound under conditions capable of forming a PQQ-iodonium complex; and sequestering PQQ in a PQQ-iodonium complex sufficient to inhibit said PQQ-catalyzed redox reaction.
33. A method of killing unwanted vegetation, said method comprising;
obtaining an iodonium compound capable of sequestering PQQ; and
dispersing said iodonium compound on the surface of said unwanted vegetation sufficient to sequester PQQ and kill said vegetation.
34. A method of killing marine pests, said method comprising:
obtaining an iodonium compound capable of sequestering PQQ;
dissolving said iodonium compound in a aqueous solvent; and
dispersing said solution over an area subject to marine pest infestation in an amount sufficient to kill said marine pests.
35. A topical fungicide comprising an iodonium compound capable of being inactivated after skin
penetration.
36. The method of claim 28, said vegetation being the kudzu vine.
37. The method of claim 29, said marine pests being any one of zebra mussels, lamprey eels, or
starfish.
38. A method of inhibiting inflammation in a mammal, said method comprising
obtaining an iodonium compound capable of sequestering PQQ; administering said iodonium compound;
contacting PQQ with said iodonium compound under conditions capable of forming a PQQ-iodonium complex; and sequestering PQQ in a PQQ-iodonium complex sufficient to inhibit said inflammation.
39. A method of inhibiting microbial growth on a tissue surface or teeth from a human or veterinary patient, said method comprising:
providing an iodonium compound exhibiting anti-microbial activity; and
topically applying said iodonium compound to said tissue surface or tooth in an amount sufficient to inhibit growth of susceptible microbes on said tissue surface or tooth.
40. The method of claim 37, wherein said tissue surface is in the oral cavity, said oral cavity being characterized by at least one of dental caries, plaque, gingivitis, periodontitis, gingivitis-induced
inflammation or thrush.
41. The method of claim 37, wherein said tissue surface is a skin surface outside the oral cavity.
42. The method of claim 37, wherein said tissue surface has been subjected to dental surgery and said applying is in the form of an oral rinse, oral irrigant, periodontal pack or pharmaceutically acceptable vehicle.
43. The method of claim 37, said method further comprising providing and applying chlorhexidine.
44. The method of claim 37, wherein after said topically applying, said iodonium compound is inactivated by administering a non-toxic reducing agent.
45. The method of claim 42, wherein said non-toxic reducing agent is ascorbate.
46. The method of claim 37, wherein either prior to or during said topically applying, a boric acid solution is administered in an amount sufficient to enhance the anti-microbial activity of said iodonium compound.
47. The method of claim 44, wherein after said topically applying, said iodonium compound is inactivated by administering a non-toxic reducing agent.
48. The method of claim 45, wherein said non-toxic reducing agent is ascorbate.
49. The method of claim 36, said mammal being a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14018/95A AU1401895A (en) | 1993-12-16 | 1994-12-16 | Triflate-mediated preparation and use of iodonium compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16885093A | 1993-12-16 | 1993-12-16 | |
US08/168,850 | 1993-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995016671A1 true WO1995016671A1 (en) | 1995-06-22 |
Family
ID=22613186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/014410 WO1995016671A1 (en) | 1993-12-16 | 1994-12-16 | Triflate-mediated preparation and use of iodonium compounds |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1401895A (en) |
WO (1) | WO1995016671A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1011029A2 (en) * | 1998-11-10 | 2000-06-21 | JSR Corporation | Radiation-sensitive resin composition |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3422152A (en) * | 1966-01-05 | 1969-01-14 | Parke Davis & Co | Dihalogenated alkoxydiphenyliodonium salts |
US3622586A (en) * | 1969-05-21 | 1971-11-23 | Dow Chemical Co | Pyridyliodonium salts |
US3734928A (en) * | 1970-08-11 | 1973-05-22 | Dow Chemical Co | Difunctional iodonium salts of diphenyl oxide and preparation |
US3759989A (en) * | 1970-11-02 | 1973-09-18 | Dow Chemical Co | Bis(p-phenoxyphenyl)iodonium salts |
US3862333A (en) * | 1973-03-23 | 1975-01-21 | Smithkline Corp | Methods and compositions for inhibiting rumen microbial deamination |
US4348525A (en) * | 1981-04-09 | 1982-09-07 | The University Of Akron | Composition and a process for the preparation of [hydroxy(organosulfonyloxy)iodo]arenes and their use in a regiospecific synthesis of diaryliodonium salts |
US4513137A (en) * | 1981-04-09 | 1985-04-23 | The University Of Akron | Iodonium salts |
US4623666A (en) * | 1984-11-06 | 1986-11-18 | Kennedy Thomas P | Pharmacological applications of diphenylhalonium ion |
US4786441A (en) * | 1987-08-24 | 1988-11-22 | International Business Machines Corporation | Preparation of iodonium and sulfonium triflates |
US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US5286901A (en) * | 1990-03-09 | 1994-02-15 | University Of Utah Research Foundation | Prescursors for and synthesis of mono- and difunctionalized acetylenes and difunctional 1,3-diynes |
-
1994
- 1994-12-16 AU AU14018/95A patent/AU1401895A/en not_active Abandoned
- 1994-12-16 WO PCT/US1994/014410 patent/WO1995016671A1/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3422152A (en) * | 1966-01-05 | 1969-01-14 | Parke Davis & Co | Dihalogenated alkoxydiphenyliodonium salts |
US3622586A (en) * | 1969-05-21 | 1971-11-23 | Dow Chemical Co | Pyridyliodonium salts |
US3734928A (en) * | 1970-08-11 | 1973-05-22 | Dow Chemical Co | Difunctional iodonium salts of diphenyl oxide and preparation |
US3759989A (en) * | 1970-11-02 | 1973-09-18 | Dow Chemical Co | Bis(p-phenoxyphenyl)iodonium salts |
US3862333A (en) * | 1973-03-23 | 1975-01-21 | Smithkline Corp | Methods and compositions for inhibiting rumen microbial deamination |
US4348525A (en) * | 1981-04-09 | 1982-09-07 | The University Of Akron | Composition and a process for the preparation of [hydroxy(organosulfonyloxy)iodo]arenes and their use in a regiospecific synthesis of diaryliodonium salts |
US4513137A (en) * | 1981-04-09 | 1985-04-23 | The University Of Akron | Iodonium salts |
US4623666A (en) * | 1984-11-06 | 1986-11-18 | Kennedy Thomas P | Pharmacological applications of diphenylhalonium ion |
US4786441A (en) * | 1987-08-24 | 1988-11-22 | International Business Machines Corporation | Preparation of iodonium and sulfonium triflates |
US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
US5286901A (en) * | 1990-03-09 | 1994-02-15 | University Of Utah Research Foundation | Prescursors for and synthesis of mono- and difunctionalized acetylenes and difunctional 1,3-diynes |
Non-Patent Citations (5)
Title |
---|
CHEM. LETTERS, Vol. 11, issued 1992, KITAMURA et al., "Novel Alkynyl-Substituted (p-Phenylene)Bisiodonium Ditriflates", pages 2241-2244. * |
JOURNAL OF ORGANIC CHEMISTRY, Vol. 56, No. 12, issued 1991, BACHI et al., "Synthesis of Alkynl(Phenyl)Iodonium Triflates and Their Reaction With Diethyl 2-Aminomalate", pages 3912-3915. * |
JOURNAL OF PHARMACOL. AND EXP. THER., Vol. 255, No. 3, issued 1990, HAMAGISHI et al., "New Biological Properties of Pyrroloquinone and Its Related Compounds: Inhibition of Chemiluminescence, Lipid Peroxidation and Rat Paw Edema", pages 980-985. * |
TETRAHEDRON LETTERS, Vol. 34, No. 43, issued 1993, ZHDANKIN et al., "A General Approach to Aryl(Cyano)Iodonium Triflates - Versatile Iodonium Transfer Reagents", pages 6853-6856. * |
THE FASEB JOURNAL, Vol. 5, No. 1, issued January 1991, STUEHR et al., "Inhibition of Macrophage and Endothelial Cell Nitric Oxide Synthase by Diphenyliodonium and Its Analogs", pages 98-103. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1011029A2 (en) * | 1998-11-10 | 2000-06-21 | JSR Corporation | Radiation-sensitive resin composition |
EP1011029A3 (en) * | 1998-11-10 | 2001-01-17 | JSR Corporation | Radiation-sensitive resin composition |
US6337171B1 (en) | 1998-11-10 | 2002-01-08 | Jsr Corporation | Radiation-sensitive resin composition |
Also Published As
Publication number | Publication date |
---|---|
AU1401895A (en) | 1995-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11673129B2 (en) | Radical generating catalyst, method for producing radical, method for producing oxidation reaction product, drug, and drug for agriculture and livestock | |
AU2006208046B2 (en) | N-halogenated amino acids and N, N-dihalogenated amino acids in combination with hypohalous acids | |
CN110769931B (en) | Free radical generating catalyst, method for producing free radical, method for producing oxidation reaction product, pharmaceutical agent, and agricultural and livestock pharmaceutical agent | |
JP4994033B2 (en) | N, N-dihalogenated amino acids and derivatives | |
US20090148540A1 (en) | Antibacterial composition and method of production | |
Modak et al. | Sulfadiazine silver-resistant Pseudomonas in burns: new topical agents | |
TW200843787A (en) | N-halogenated amino compounds and derivatives; compositions and methods of using them | |
EP3375491A1 (en) | Antimicrobially active composition having a content of bispyridinium alkane (octenidine dihydrochloride) | |
JPH0635368B2 (en) | Composition comprising biguanide and pyrimidine having high bactericidal activity | |
JP2017534570A (en) | Iodophor composition with improved stability in the presence of organic materials | |
FR2648133A1 (en) | N-SUBSTITUTED LAURAMIDES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | |
US6579541B2 (en) | Oxidative fluorinator compounds as antimicrobials | |
EP0049593A1 (en) | 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid and metal salts thereof useful in burn therapy | |
JPS5828862B2 (en) | Iodinated derivative of benzalkonium clothod, its production method, and fungicide containing the derivative as an active ingredient | |
KR20230077730A (en) | Methods and Uses of Creating Compositions Stably Containing Free Available Chlorine Species and Peroxides | |
WO1995016671A1 (en) | Triflate-mediated preparation and use of iodonium compounds | |
CN114269159A (en) | Compositions, kits, methods and uses for preventing microbial growth | |
US4288609A (en) | Quaternary ammonium derivatives of adamantane with antimicrobic activity | |
DE69702158T2 (en) | Carnitine bisalkanoyl esters with bactericidal, fungicidal and antiprotozoic effects | |
EP0275207B1 (en) | Pharmaceutical and veterinary compositions | |
RU2203035C1 (en) | Pharmaceutical composition with disinfecting, sporocidal and wound-healing properties | |
DE2002801A1 (en) | Method for combating pathogenic microorganisms such as fungi and bacteria, and the means used for this | |
CH626229A5 (en) | ||
JPH0558971A (en) | Aminoester compound salt and disinfectant | |
JPH0649007A (en) | Fungicidal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |